AU2011265545A1 - Use of effectors of glutaminyl and glutamate cyclases - Google Patents
Use of effectors of glutaminyl and glutamate cyclases Download PDFInfo
- Publication number
- AU2011265545A1 AU2011265545A1 AU2011265545A AU2011265545A AU2011265545A1 AU 2011265545 A1 AU2011265545 A1 AU 2011265545A1 AU 2011265545 A AU2011265545 A AU 2011265545A AU 2011265545 A AU2011265545 A AU 2011265545A AU 2011265545 A1 AU2011265545 A1 AU 2011265545A1
- Authority
- AU
- Australia
- Prior art keywords
- gln
- gin
- activity
- impaired
- substrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012636 effector Substances 0.000 title claims abstract description 81
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 title claims description 36
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title description 46
- 229930195712 glutamate Natural products 0.000 title description 15
- 101710095468 Cyclase Proteins 0.000 title description 4
- 230000000694 effects Effects 0.000 claims abstract description 146
- 239000000758 substrate Substances 0.000 claims abstract description 123
- 102000004190 Enzymes Human genes 0.000 claims abstract description 109
- 108090000790 Enzymes Proteins 0.000 claims abstract description 109
- 239000003112 inhibitor Substances 0.000 claims abstract description 74
- 238000000034 method Methods 0.000 claims abstract description 69
- 108010081484 glutaminyl-peptide cyclotransferase Proteins 0.000 claims abstract description 22
- 102000003642 glutaminyl-peptide cyclotransferase Human genes 0.000 claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 238000012216 screening Methods 0.000 claims abstract description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 114
- 229940088598 enzyme Drugs 0.000 claims description 108
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 88
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 73
- 238000006243 chemical reaction Methods 0.000 claims description 68
- 150000001875 compounds Chemical class 0.000 claims description 67
- 230000001771 impaired effect Effects 0.000 claims description 42
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 41
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 36
- 210000004027 cell Anatomy 0.000 claims description 35
- 230000033228 biological regulation Effects 0.000 claims description 28
- 241000124008 Mammalia Species 0.000 claims description 26
- 108010052343 Gastrins Proteins 0.000 claims description 24
- -1 5-oxo-prolyl) residues Chemical group 0.000 claims description 23
- 208000024827 Alzheimer disease Diseases 0.000 claims description 22
- 235000013922 glutamic acid Nutrition 0.000 claims description 22
- 239000004220 glutamic acid Substances 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 101800001814 Neurotensin Proteins 0.000 claims description 19
- 229960001340 histamine Drugs 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 17
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 17
- 230000004044 response Effects 0.000 claims description 17
- 102000004400 Aminopeptidases Human genes 0.000 claims description 15
- 108090000915 Aminopeptidases Proteins 0.000 claims description 15
- 201000010374 Down Syndrome Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 238000001727 in vivo Methods 0.000 claims description 14
- 239000000969 carrier Substances 0.000 claims description 13
- 230000004663 cell proliferation Effects 0.000 claims description 12
- 230000035558 fertility Effects 0.000 claims description 12
- 229910021645 metal ion Inorganic materials 0.000 claims description 12
- 230000035755 proliferation Effects 0.000 claims description 12
- 230000003284 homeostatic effect Effects 0.000 claims description 11
- 210000001711 oxyntic cell Anatomy 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 201000001320 Atherosclerosis Diseases 0.000 claims description 10
- 102000002512 Orexin Human genes 0.000 claims description 10
- 210000003038 endothelium Anatomy 0.000 claims description 10
- 230000005012 migration Effects 0.000 claims description 10
- 238000013508 migration Methods 0.000 claims description 10
- 108060005714 orexin Proteins 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 206010062519 Poor quality sleep Diseases 0.000 claims description 9
- 201000004681 Psoriasis Diseases 0.000 claims description 9
- 230000009858 acid secretion Effects 0.000 claims description 9
- 230000009471 action Effects 0.000 claims description 9
- 230000037424 autonomic function Effects 0.000 claims description 9
- 210000001124 body fluid Anatomy 0.000 claims description 9
- 239000010839 body fluid Substances 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 230000037149 energy metabolism Effects 0.000 claims description 9
- 230000037406 food intake Effects 0.000 claims description 9
- 235000012631 food intake Nutrition 0.000 claims description 9
- 230000003054 hormonal effect Effects 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 9
- 230000009826 neoplastic cell growth Effects 0.000 claims description 9
- OFNHNCAUVYOTPM-IIIOAANCSA-N orexin-a Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N2)[C@@H](C)O)=O)CSSC1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NC(=O)CC1)C1=CNC=N1 OFNHNCAUVYOTPM-IIIOAANCSA-N 0.000 claims description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 9
- 230000003248 secreting effect Effects 0.000 claims description 9
- 108010078239 Chemokine CX3CL1 Proteins 0.000 claims description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 8
- 230000004069 differentiation Effects 0.000 claims description 8
- 206010017758 gastric cancer Diseases 0.000 claims description 8
- 230000002496 gastric effect Effects 0.000 claims description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 8
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 claims description 8
- 238000012544 monitoring process Methods 0.000 claims description 8
- 210000003643 myeloid progenitor cell Anatomy 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 201000000980 schizophrenia Diseases 0.000 claims description 8
- 201000011549 stomach cancer Diseases 0.000 claims description 8
- 102000013818 Fractalkine Human genes 0.000 claims description 7
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims description 7
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 7
- 230000001154 acute effect Effects 0.000 claims description 7
- 210000004188 enterochromaffin-like cell Anatomy 0.000 claims description 7
- 210000002919 epithelial cell Anatomy 0.000 claims description 7
- 208000000509 infertility Diseases 0.000 claims description 7
- 230000036512 infertility Effects 0.000 claims description 7
- 231100000535 infertility Toxicity 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- 230000035790 physiological processes and functions Effects 0.000 claims description 7
- 230000004936 stimulating effect Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 208000028017 Psychotic disease Diseases 0.000 claims description 6
- 208000025865 Ulcer Diseases 0.000 claims description 6
- 230000004075 alteration Effects 0.000 claims description 6
- 230000028996 humoral immune response Effects 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 6
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 230000001629 suppression Effects 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 5
- OKGNKPYIPKMGLR-ZPCKCTIPSA-N gastrins Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NC(=O)CC1)C1=CN=CN1 OKGNKPYIPKMGLR-ZPCKCTIPSA-N 0.000 claims description 5
- 230000009401 metastasis Effects 0.000 claims description 5
- 230000000638 stimulation Effects 0.000 claims description 5
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000027747 Kennedy disease Diseases 0.000 claims description 2
- 101100068676 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) gln-1 gene Proteins 0.000 claims description 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 2
- 229940097396 Aminopeptidase inhibitor Drugs 0.000 claims 4
- 102000050267 Neurotensin Human genes 0.000 claims 4
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 claims 4
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 19
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 70
- 230000015572 biosynthetic process Effects 0.000 description 56
- 238000007363 ring formation reaction Methods 0.000 description 55
- 238000005755 formation reaction Methods 0.000 description 53
- 235000009467 Carica papaya Nutrition 0.000 description 48
- 101000585315 Homo sapiens Glutaminyl-peptide cyclotransferase Proteins 0.000 description 44
- 241000219173 Carica Species 0.000 description 38
- 238000003556 assay Methods 0.000 description 35
- 235000004554 glutamine Nutrition 0.000 description 34
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 33
- 230000005764 inhibitory process Effects 0.000 description 33
- 239000000243 solution Substances 0.000 description 32
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 32
- 238000006555 catalytic reaction Methods 0.000 description 31
- 150000003839 salts Chemical class 0.000 description 29
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 23
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 22
- 230000002255 enzymatic effect Effects 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 102400000921 Gastrin Human genes 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 19
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 19
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 238000001819 mass spectrum Methods 0.000 description 18
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 17
- 241000196324 Embryophyta Species 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 17
- 108010016626 Dipeptides Proteins 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 16
- 240000006432 Carica papaya Species 0.000 description 15
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 102400001103 Neurotensin Human genes 0.000 description 15
- 238000003776 cleavage reaction Methods 0.000 description 15
- 108700021111 pyroglutamyl-glutamyl-proline amide Proteins 0.000 description 15
- 230000007017 scission Effects 0.000 description 15
- HYZBGWLLSXSYLX-GUBZILKMSA-N Pglu-glu-pro-amide Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1NC(=O)CC1 HYZBGWLLSXSYLX-GUBZILKMSA-N 0.000 description 14
- 239000007983 Tris buffer Substances 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 239000011159 matrix material Substances 0.000 description 14
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 14
- 230000007306 turnover Effects 0.000 description 14
- 229960004666 glucagon Drugs 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 102000051325 Glucagon Human genes 0.000 description 12
- 108060003199 Glucagon Proteins 0.000 description 12
- 230000015556 catabolic process Effects 0.000 description 12
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 239000002243 precursor Substances 0.000 description 12
- 238000012545 processing Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000006731 degradation reaction Methods 0.000 description 11
- 229910052751 metal Inorganic materials 0.000 description 11
- 239000002184 metal Substances 0.000 description 11
- 210000001616 monocyte Anatomy 0.000 description 11
- 230000001817 pituitary effect Effects 0.000 description 11
- 230000007420 reactivation Effects 0.000 description 11
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 229910021529 ammonia Inorganic materials 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 7
- 125000004060 L-alloisoleucine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000007853 buffer solution Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 230000003197 catalytic effect Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 7
- 229960002885 histidine Drugs 0.000 description 7
- 150000002460 imidazoles Chemical class 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 239000004816 latex Substances 0.000 description 7
- 229920000126 latex Polymers 0.000 description 7
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 6
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 6
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 239000012190 activator Substances 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 5
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 5
- 208000037259 Amyloid Plaque Diseases 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 101001129465 Homo sapiens Pyroglutamyl-peptidase 1 Proteins 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102100031108 Pyroglutamyl-peptidase 1 Human genes 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 5
- 235000011130 ammonium sulphate Nutrition 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 229940043131 pyroglutamate Drugs 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 4
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 4
- 102000003797 Neuropeptides Human genes 0.000 description 4
- 108090000189 Neuropeptides Proteins 0.000 description 4
- 102000015636 Oligopeptides Human genes 0.000 description 4
- 108010038807 Oligopeptides Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000164 antipsychotic agent Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000003399 chemotactic effect Effects 0.000 description 4
- 239000005482 chemotactic factor Substances 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000006167 equilibration buffer Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000036962 time dependent Effects 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 3
- UMMQVDUMUMBTAV-YFKPBYRVSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanamide Chemical compound NC(=O)[C@@H](N)CC1=CN=CN1 UMMQVDUMUMBTAV-YFKPBYRVSA-N 0.000 description 3
- FZQXMGLQANXZRP-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-3-(3-imidazol-1-ylpropyl)thiourea Chemical compound C1=C(OC)C(OC)=CC=C1NC(=S)NCCCN1C=NC=C1 FZQXMGLQANXZRP-UHFFFAOYSA-N 0.000 description 3
- 101800000285 Big gastrin Proteins 0.000 description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 3
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 241000235058 Komagataella pastoris Species 0.000 description 3
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 3
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 102400000096 Substance P Human genes 0.000 description 3
- 101800003906 Substance P Proteins 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- 102000030621 adenylate cyclase Human genes 0.000 description 3
- 108060000200 adenylate cyclase Proteins 0.000 description 3
- 101150031224 app gene Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 125000003164 beta-aspartyl group Chemical group 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 230000035605 chemotaxis Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 238000006317 isomerization reaction Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- 230000000269 nucleophilic effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000000813 peptide hormone Substances 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 235000013930 proline Nutrition 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007974 sodium acetate buffer Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- VEPDWBJBPXVCEN-NSHDSACASA-N (2s)-2-amino-n-(4-methyl-2-oxochromen-7-yl)pentanediamide Chemical compound C1=C(NC(=O)[C@@H](N)CCC(N)=O)C=CC2=C1OC(=O)C=C2C VEPDWBJBPXVCEN-NSHDSACASA-N 0.000 description 2
- SKSRYSIARQUAOA-VIFPVBQESA-N (2s)-2-amino-n-(4-nitrophenyl)pentanediamide Chemical compound NC(=O)CC[C@H](N)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 SKSRYSIARQUAOA-VIFPVBQESA-N 0.000 description 2
- YZJSUQQZGCHHNQ-BYPYZUCNSA-N (2s)-6-amino-2-azaniumyl-6-oxohexanoate Chemical group OC(=O)[C@@H](N)CCCC(N)=O YZJSUQQZGCHHNQ-BYPYZUCNSA-N 0.000 description 2
- ARNUPLMOASAEAN-ASLNEKEESA-N (2s,3s)-2-amino-3-methyl-1-(1,3-thiazolidin-2-yl)pentan-1-one Chemical compound CC[C@H](C)[C@H](N)C(=O)C1NCCS1 ARNUPLMOASAEAN-ASLNEKEESA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- KKKDZZRICRFGSD-UHFFFAOYSA-N 1-benzylimidazole Chemical compound C1=CN=CN1CC1=CC=CC=C1 KKKDZZRICRFGSD-UHFFFAOYSA-N 0.000 description 2
- OSSNTDFYBPYIEC-UHFFFAOYSA-N 1-ethenylimidazole Chemical compound C=CN1C=CN=C1 OSSNTDFYBPYIEC-UHFFFAOYSA-N 0.000 description 2
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 2
- SEULWJSKCVACTH-UHFFFAOYSA-N 1-phenylimidazole Chemical compound C1=NC=CN1C1=CC=CC=C1 SEULWJSKCVACTH-UHFFFAOYSA-N 0.000 description 2
- YPTJKHVBDCRKNF-UHFFFAOYSA-N 2',6'-Dihydroxyacetophenone Chemical compound CC(=O)C1=C(O)C=CC=C1O YPTJKHVBDCRKNF-UHFFFAOYSA-N 0.000 description 2
- JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical compound C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 2
- DVUFTQLHHHJEMK-IMJSIDKUSA-N Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O DVUFTQLHHHJEMK-IMJSIDKUSA-N 0.000 description 2
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 2
- 102100023700 C-C motif chemokine 16 Human genes 0.000 description 2
- 102100023701 C-C motif chemokine 18 Human genes 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108090000267 Cathepsin C Proteins 0.000 description 2
- 102000003902 Cathepsin C Human genes 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 2
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 2
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 2
- 102100029846 Glutaminyl-peptide cyclotransferase Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000978375 Homo sapiens C-C motif chemokine 16 Proteins 0.000 description 2
- 101000978371 Homo sapiens C-C motif chemokine 18 Proteins 0.000 description 2
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 2
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 2
- 101000967820 Homo sapiens Inactive dipeptidyl peptidase 10 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 102100040449 Inactive dipeptidyl peptidase 10 Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108010010995 MART-1 Antigen Proteins 0.000 description 2
- 102000016200 MART-1 Antigen Human genes 0.000 description 2
- UUIQMZJEGPQKFD-UHFFFAOYSA-N Methyl butyrate Chemical compound CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- XYONNSVDNIRXKZ-UHFFFAOYSA-N S-methyl methanethiosulfonate Chemical compound CSS(C)(=O)=O XYONNSVDNIRXKZ-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000003141 Tachykinin Human genes 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 239000007997 Tricine buffer Substances 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 238000005844 autocatalytic reaction Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 2
- GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 230000008556 epithelial cell proliferation Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000007421 fluorometric assay Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- JEGIFBGJZPYMJS-UHFFFAOYSA-N imidazol-1-yl(phenyl)methanone Chemical compound C1=CN=CN1C(=O)C1=CC=CC=C1 JEGIFBGJZPYMJS-UHFFFAOYSA-N 0.000 description 2
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 235000014705 isoleucine Nutrition 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 150000003951 lactams Chemical group 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000007257 malfunction Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229960003540 oxyquinoline Drugs 0.000 description 2
- 230000004963 pathophysiological condition Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 108010040003 polyglutamine Proteins 0.000 description 2
- 229920000155 polyglutamine Polymers 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- RZIMNEGTIDYAGZ-HNSJZBNRSA-N pro-gastrin Chemical compound N([C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C(=O)[C@@H]1CCC(=O)N1 RZIMNEGTIDYAGZ-HNSJZBNRSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003235 pyrrolidines Chemical class 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000008010 sperm capacitation Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 108060008037 tachykinin Proteins 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 235000014393 valine Nutrition 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- AHBLWCWWXZJIIR-UHFFFAOYSA-N (1-cyclohexyl-3,3-dimethyl-1-oxobutan-2-yl)azanium;chloride Chemical compound [Cl-].CC(C)(C)C([NH3+])C(=O)C1CCCCC1 AHBLWCWWXZJIIR-UHFFFAOYSA-N 0.000 description 1
- NGHKPFDSWWVQRM-UHFFFAOYSA-N (1-cyclopentyl-3-methyl-1-oxobutan-2-yl)azanium;chloride Chemical compound [Cl-].CC(C)C([NH3+])C(=O)C1CCCC1 NGHKPFDSWWVQRM-UHFFFAOYSA-N 0.000 description 1
- QOMLWUOJCBLHPI-UHFFFAOYSA-N (1-cyclopentyl-3-methyl-1-oxopentan-2-yl)azanium;chloride Chemical compound [Cl-].CCC(C)C([NH3+])C(=O)C1CCCC1 QOMLWUOJCBLHPI-UHFFFAOYSA-N 0.000 description 1
- XGNBIYXILDDDQR-DTWKUNHWSA-N (2s)-1-[(2s)-2-amino-3,3-dimethylbutanoyl]pyrrolidine-2-carbonitrile Chemical compound CC(C)(C)[C@H](N)C(=O)N1CCC[C@H]1C#N XGNBIYXILDDDQR-DTWKUNHWSA-N 0.000 description 1
- BMJRTKDVFXYEFS-XIFFEERXSA-N (2s)-2,6-bis(9h-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(=O)O)CCCCNC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 BMJRTKDVFXYEFS-XIFFEERXSA-N 0.000 description 1
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 1
- YPTNAIDIXCOZAJ-LHEWISCISA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[[(4-methylphenyl)-diphenylmethyl]amino]hexanoic acid Chemical compound C1=CC(C)=CC=C1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)NCCCC[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 YPTNAIDIXCOZAJ-LHEWISCISA-N 0.000 description 1
- NEHKZPHIKKEMAZ-ZFVKSOIMSA-N (2s)-2-[[(2s,3r)-2-[[(2s)-2-[[(2s,3s)-2-[[2-[[(2s,3s)-2-[[2-[[(2s)-2-[[(2s)-2-azaniumylpropanoyl]amino]propanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylb Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O NEHKZPHIKKEMAZ-ZFVKSOIMSA-N 0.000 description 1
- IVBVTDXOGUNDHC-LURJTMIESA-N (2s)-2-amino-1-pyrrolidin-1-ylpropan-1-one Chemical compound C[C@H](N)C(=O)N1CCCC1 IVBVTDXOGUNDHC-LURJTMIESA-N 0.000 description 1
- ZQVXEHAYROEWBT-WPRPVWTQSA-N (2s)-2-amino-n-[(2s)-1-amino-1-oxopropan-2-yl]-3-phenylpropanamide Chemical compound NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 ZQVXEHAYROEWBT-WPRPVWTQSA-N 0.000 description 1
- QFKUSGBKEGSBMQ-XJPBFQKESA-N (2s)-2-amino-n-[(2s)-3-methyl-1-oxo-1-[(2s)-2-(pyridine-2-carbonyl)pyrrolidin-1-yl]butan-2-yl]propanamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)C1=CC=CC=N1 QFKUSGBKEGSBMQ-XJPBFQKESA-N 0.000 description 1
- VCODUTUPBPSXRA-LBRAPMIBSA-N (2s)-n-[(2s)-1-[(2s)-2-acetylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-2-aminopropanamide;hydrobromide Chemical compound Br.C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(C)=O VCODUTUPBPSXRA-LBRAPMIBSA-N 0.000 description 1
- RICKQPKTSOSCOF-HKUYNNGSSA-N (3s)-2-[(2s)-2-amino-3-(1h-indol-3-yl)propanoyl]-3,4-dihydro-1h-isoquinoline-3-carboxylic acid Chemical compound C1C2=CC=CC=C2C[C@@H](C(O)=O)N1C(=O)[C@@H](N)CC1=CNC2=CC=CC=C12 RICKQPKTSOSCOF-HKUYNNGSSA-N 0.000 description 1
- GOPWHXPXSPIIQZ-FQEVSTJZSA-N (4s)-4-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(O)=O)C(=O)OC(C)(C)C)C3=CC=CC=C3C2=C1 GOPWHXPXSPIIQZ-FQEVSTJZSA-N 0.000 description 1
- AXJZCJSXNZZMDU-UHFFFAOYSA-N (5-methyl-1h-imidazol-4-yl)methanol Chemical compound CC=1N=CNC=1CO AXJZCJSXNZZMDU-UHFFFAOYSA-N 0.000 description 1
- JFMNKDRNEZZRBW-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxamide Chemical class C1=CC=C2CNC(C(=O)N)CC2=C1 JFMNKDRNEZZRBW-UHFFFAOYSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IAADPEJYEZPFOT-UHFFFAOYSA-N 1-(1h-imidazol-2-yl)propan-1-amine Chemical compound CCC(N)C1=NC=CN1 IAADPEJYEZPFOT-UHFFFAOYSA-N 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- ZLKNPIVTWNMMMH-UHFFFAOYSA-N 1-imidazol-1-ylsulfonylimidazole Chemical compound C1=CN=CN1S(=O)(=O)N1C=CN=C1 ZLKNPIVTWNMMMH-UHFFFAOYSA-N 0.000 description 1
- XGDRLCRGKUCBQL-UHFFFAOYSA-N 1h-imidazole-4,5-dicarbonitrile Chemical compound N#CC=1N=CNC=1C#N XGDRLCRGKUCBQL-UHFFFAOYSA-N 0.000 description 1
- ZQEXIXXJFSQPNA-UHFFFAOYSA-N 1h-imidazole-5-carbaldehyde Chemical compound O=CC1=CNC=N1 ZQEXIXXJFSQPNA-UHFFFAOYSA-N 0.000 description 1
- CKKOVFGIBXCEIJ-UHFFFAOYSA-N 2,6-difluorophenol Chemical compound OC1=C(F)C=CC=C1F CKKOVFGIBXCEIJ-UHFFFAOYSA-N 0.000 description 1
- OUWIVCMEYBVEHT-UHFFFAOYSA-N 2-(cyclohexylamino)-1-cyclopentylethanone;hydrochloride Chemical compound [Cl-].C1CCCC1C(=O)C[NH2+]C1CCCCC1 OUWIVCMEYBVEHT-UHFFFAOYSA-N 0.000 description 1
- UVOCKSMHKPRDMY-UHFFFAOYSA-N 2-[(2-methylphenyl)methyl]-1h-imidazole Chemical compound CC1=CC=CC=C1CC1=NC=CN1 UVOCKSMHKPRDMY-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- UDOGNMDURIJYQC-UHFFFAOYSA-N 2-amino-6-methyl-1h-pteridin-4-one Chemical compound N1C(N)=NC(=O)C2=NC(C)=CN=C21 UDOGNMDURIJYQC-UHFFFAOYSA-N 0.000 description 1
- AYPSHJCKSDNETA-UHFFFAOYSA-N 2-chloro-1h-benzimidazole Chemical compound C1=CC=C2NC(Cl)=NC2=C1 AYPSHJCKSDNETA-UHFFFAOYSA-N 0.000 description 1
- LDZYRENCLPUXAX-UHFFFAOYSA-N 2-methyl-1h-benzimidazole Chemical compound C1=CC=C2NC(C)=NC2=C1 LDZYRENCLPUXAX-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- CPHGOBGXZQKCKI-UHFFFAOYSA-N 4,5-diphenyl-1h-imidazole Chemical compound N1C=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 CPHGOBGXZQKCKI-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- JDDWRLPTKIOUOF-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-[[4-[2-[bis(4-methylphenyl)methylamino]-2-oxoethoxy]phenyl]-(2,4-dimethoxyphenyl)methyl]carbamate Chemical compound COC1=CC(OC)=CC=C1C(C=1C=CC(OCC(=O)NC(C=2C=CC(C)=CC=2)C=2C=CC(C)=CC=2)=CC=1)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JDDWRLPTKIOUOF-UHFFFAOYSA-N 0.000 description 1
- 101150006240 AOX2 gene Proteins 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010006591 Apoenzymes Proteins 0.000 description 1
- LQJAALCCPOTJGB-YUMQZZPRSA-N Arg-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O LQJAALCCPOTJGB-YUMQZZPRSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101710177589 Asp/Glu-specific dipeptidyl-peptidase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102100027936 Attractin Human genes 0.000 description 1
- 101710134735 Attractin Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102100021257 Beta-secretase 1 Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000012617 Butyl Sepharose™ 4 Fast Flow Substances 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100036841 C-C motif chemokine 1 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101100002344 Caenorhabditis elegans arid-1 gene Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 102100036966 Dipeptidyl aminopeptidase-like protein 6 Human genes 0.000 description 1
- 102100020751 Dipeptidyl peptidase 2 Human genes 0.000 description 1
- 102100020997 Fractalkine Human genes 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- FAQVCWVVIYYWRR-WHFBIAKZSA-N Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O FAQVCWVVIYYWRR-WHFBIAKZSA-N 0.000 description 1
- 101710173666 Glucagon-3 Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 description 1
- 102000003958 Glutamate Carboxypeptidase II Human genes 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 101710183768 Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- FBTYOQIYBULKEH-ZFWWWQNUSA-N His-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CNC=N1 FBTYOQIYBULKEH-ZFWWWQNUSA-N 0.000 description 1
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 1
- 101000713104 Homo sapiens C-C motif chemokine 1 Proteins 0.000 description 1
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 description 1
- 101000804935 Homo sapiens Dipeptidyl aminopeptidase-like protein 6 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- MLSUZXHSNRBDCI-CYDGBPFRSA-N Ile-Pro-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)O)N MLSUZXHSNRBDCI-CYDGBPFRSA-N 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- LCGISIDBXHGCDW-VKHMYHEASA-N L-glutamine amide Chemical compound NC(=O)[C@@H](N)CCC(N)=O LCGISIDBXHGCDW-VKHMYHEASA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
- AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- FHQDWPCFSJMNCT-UHFFFAOYSA-N N(tele)-methylhistamine Chemical compound CN1C=NC(CCN)=C1 FHQDWPCFSJMNCT-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- XJWPISBUKWZALE-UHFFFAOYSA-N N-acetylhistamine Chemical compound CC(=O)NCCC1=CN=CN1 XJWPISBUKWZALE-UHFFFAOYSA-N 0.000 description 1
- VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- YKFRUJSEPGHZFJ-UHFFFAOYSA-N N-trimethylsilylimidazole Chemical compound C[Si](C)(C)N1C=CN=C1 YKFRUJSEPGHZFJ-UHFFFAOYSA-N 0.000 description 1
- IDGQXGPQOGUGIX-VIFPVBQESA-N O-BENZYL-l-SERINE Chemical compound OC(=O)[C@@H](N)COCC1=CC=CC=C1 IDGQXGPQOGUGIX-VIFPVBQESA-N 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoserine Chemical compound OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 102100037588 Orexin receptor type 2 Human genes 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- FZBGMXYQPACKNC-HJWJTTGWSA-N Phe-Pro-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FZBGMXYQPACKNC-HJWJTTGWSA-N 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- GZGFSPWOMUKKCV-NAKRPEOUSA-N Ser-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO GZGFSPWOMUKKCV-NAKRPEOUSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000187392 Streptomyces griseus Species 0.000 description 1
- 101000733590 Streptomyces griseus subsp. griseus (strain JCM 4626 / NBRC 13350) Aminopeptidase S Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- VTMGKRABARCZAX-OSUNSFLBSA-N Thr-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O VTMGKRABARCZAX-OSUNSFLBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- CPGJELLYDQEDRK-NAKRPEOUSA-N Val-Ile-Ala Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](C)C(O)=O CPGJELLYDQEDRK-NAKRPEOUSA-N 0.000 description 1
- QSPOLEBZTMESFY-SRVKXCTJSA-N Val-Pro-Val Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O QSPOLEBZTMESFY-SRVKXCTJSA-N 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000030120 acrosome reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 230000003942 amyloidogenic effect Effects 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 150000001508 asparagines Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011437 continuous method Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 230000002367 endolytic effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 108010066264 gastrin 17 Proteins 0.000 description 1
- GKDWRERMBNGKCZ-RNXBIMIWSA-N gastrin-17 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 GKDWRERMBNGKCZ-RNXBIMIWSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009688 glial response Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000046689 human FOLH1 Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229950003188 isovaleryl diethylamide Drugs 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940115256 melanoma vaccine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 230000003039 myelosuppressive effect Effects 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- RHLMXWCISNJNDH-UHFFFAOYSA-N n-[2-[3-[[5-[3-(dimethylcarbamoyl)phenyl]-2-methoxyphenyl]sulfonylamino]anilino]ethyl]-3-methylbenzamide Chemical compound COC1=CC=C(C=2C=C(C=CC=2)C(=O)N(C)C)C=C1S(=O)(=O)NC(C=1)=CC=CC=1NCCNC(=O)C1=CC=CC(C)=C1 RHLMXWCISNJNDH-UHFFFAOYSA-N 0.000 description 1
- 210000004296 naive t lymphocyte Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 108010066823 proline dipeptidase Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 108010054321 proneurotensin Proteins 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 229940048084 pyrophosphate Drugs 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- CKNYWTABPYGPEX-UHFFFAOYSA-N pyrrolidin-1-ium;2,2,2-trifluoroacetate Chemical compound C1CC[NH2+]C1.[O-]C(=O)C(F)(F)F CKNYWTABPYGPEX-UHFFFAOYSA-N 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 230000007507 senile plaque formation Effects 0.000 description 1
- 208000022288 senile plaque formation Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- UMCYUPVKJYJUCD-UHFFFAOYSA-M sodium 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]acetic acid hydroxide Chemical compound [OH-].[Na+].OCC(CO)(CO)NCC(O)=O UMCYUPVKJYJUCD-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000006250 specific catalysis Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screening for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP [V-activity.
Description
Section 29 Regulation 3.2(2) AUSTRALIA Patents Act 1990 COMPLETE SPECIFICATION STANDARD PATENT Application Number: Lodged: Invention Title: Use of effectors of glutaminyl and glutamate cyclases The following statement is a full description of this invention, including the best method of performing it known to us: Use of Effectors of Glutaminyl and Glutamate Cyclases Field of the Invention The invention relates to glutaminyl cyclase (QC, EC 2.3.2.5) that catalyzes the intramolecular cycli2:ation of N-terminal glutamine residues into pyroglutamic acid (5 oxo-proline, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water. The present invention identifies mammalian QCs as metalloenzymes, provides novel physiological substrates of 0C in mammals and the use of effectors of QC and pharmaceutical compositions comprising effectors of QC for the treatment of conditions that can be treated by modulation of 0C-activity. Additionally, it is shown that metal interaction is a useful approach for development of QC inhibitors. In a preferred embodiment, the present invention provides the use of effectors of QC activity in combination with inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and/or DP IV-activity. A screening method is also provided for the identification and selection of effectors of QC activity. Background Glutaminyl cyclase (0C, EC 2.3.2.5) catalyzes the intramolecular cyclization of N terminal glutamine residues into pyroglutamic acid (pGlu*) liberating ammonia. A 0C was first isolated by Messer from the latex of the tropical plant Carica papaya in 1963 (Messer, M. 1963 Nature 4874, 1299). 24 years later, a corresponding enzymatic activity was discovered in animal pituitary (Busby, W. H. J. et al. 1987 J Biol Chem 262, 8532-8536; Fischer, W. H. and Spiess, J. 1987 Proc Nat/ Acad Sci U S A 84, 3628-3632). For the mammalian QC, the conversion of Gin into pGlu by QC could be shown for the precursors of TRH and GnRH (Busby, W. H. J. et al. 1987 J Biol Chem 2 262, 8532-8536; Fischer, W. H. and Spiess, J. 1987 Proc Nat/ Acad Sci U S A 84, 3628-3632). In addition, initial localization experiments of QC revealed a co localization with its putative products of catalysis in bovine pituitary, further improving the suggested function in peptide hormone synthesis (Bockers, T. M. et al. 1995 J Neuroendocrino/ 7, 445-453). In contrast, the physiological function of the plant QC is less clear. In case of the enzyme from C. papaya, a role in the plant defense against pathogenic microorganisms was suggested (El Moussaoui, A. et al.2001 Cell Mo! Life Sci 58, 556-570). Putative QCs from other plants were identified by sequence comparisons recently (Dahl, S. W. et al.2000 Protein Expr Purif 20, 27-36) The physiological function of these enzymes, however, is still ambiguous. The QCs known from plants and animals show a strict specificity for L-Glutamine in the N-terminal position of the substrates and their kinetic behavior was found to obey the Michaelis-Menten equation (Pohl, T. et al. 1991 Proc Nat/ Acad Sci U S A 88, 10059-10063; Consalvo, A. P. et al. 1988 Anal Biochem 175,131-138; Gololobov, M. Y. et al. 1996 Biol Chem Hoppe Seyler 377, 395-398). A comparison of the primary structures of the QCs from C. papaya and that of the highly conserved QC from mammals, however, did not reveal any sequence homology (Dahl, S. W. et al. 2000 Protein Expr Purif 20, 27-36). Whereas the plant OCs appear to belong to a new enzyme family (Dahl, S. W. et al. 2000 Protein Expr Purif 20, 27-36), the mammalian QCs were found to have a pronounced sequence homology to bacterial aminopeptidases (Bateman, R. C. et al. 2001 Biochemistry 40, 11246-11250), leading to the conclusion that the QCs from plants and animals have different evolutionary origins. EP 02 011 349.4 discloses polynucletides encoding insect glutaminyl cyclase, as well as polypeptides encoded thereby. This application further provides host cells comprising expression vectors comprising polynucleotides of the invention. Isolated polypeptides and host cells comprising insect QC are useful in methods of screening for agents that reduce glutaminyl cyclase activity. Such agents are described as useful as pesticides.
3 Alzheimer's disease (AD) is characterized by abnormal accumulation of extracellular amyloidotic plaques closely associated with dystrophic neurones, reactive astrocytes and microglia (Terry, R. D. and Katzman, R. 1983 Ann Neurol 14, 497-506; Glenner, G. G. and Wong, C. W. 1984 Biochem Biophys Res Comm 120, 885-890; Intagaki, S. et al. 1989 J Neuroimmunol 24,173-182; Funato, H. et al. 1998 Am J Pathol 152, 983-992; Selkoe, D. J. 2001 Physiol Rev 81, 741-766). Amyloid-p (As) peptides are the primary components of senile plaques and are considered to be directly involved in the pathogenesis and progression of AD, a hypothesis supported by genetic studies (Glenner, G. G. and Wong, C. W. 1984 Biochem Biophys Res Comm 120, 885-890; Borchelt, D. R. et al. 1996 Neuron 17,1005-1013; Lemere, C. A. et al. 1996 Nat Med 2, 1146-1150; Mann, D. M. and lwatsubo, T. 1996 Neurodegeneration 5, 115-120; Citron, M. et al. 1997 Nat Med 3, 67-72; Selkoe, D. J. 2001 Physiol Rev 81, 741-766 ). AO is generated by proteolytic processing of the p-amyloid precursor protein (APP) (Kang, J. et al. 1987 Nature 325, 733-736; Selkoe, D. J. 1998 Trends Cell Biol 8, 447-453), which is sequentially cleaved by p-secretase at the N-terminus and by y-secretase at the C-terminus of AD (Haass, C. and Selkoe, 0. J. 1993 Cell 75, 1039-1042; Simons, M. et al. 1996 J Neurosci 16 899-908). In addition to the dominant As peptides starting with L-Asp at the N-terminus (Ap1-42/40), a great heterogeneity of N-terminally truncated forms occurs in senile plaques. Such shortened peptides are reported to be more neurotoxic in vitro and to aggregate more rapidly than the full-length isoforms (Pike, C. J. et al. 1995 J Biol Chem 270 23895-23898). N-truncated peptides are known to be overproduced in early onset familial AD (FAD) subjects (Saido, T. C. et al. 1995 Neuron 14, 457-466; Russo, C. et al. 2000 Nature 405, 531-532), to appear early and to increase with age in Down's syndrome (DS) brains (Russo, C. et al. 1997 FEBS Lett 409, 411-416, Russo, C. et al. 2001 Neurobio/ Dis 8, 173-180; Tekirian, T. L. et al. 1998 J Neuropathol Exp Neurol 57, 76-94). Finally, their amount reflects the progressive severity of the disease (Russo, C. et al. 1997 FEBS Lett 409, 411-416). Additional post-translational processes may further modify the N-terminus by isomerization or racemization of the aspartate at position 1 and 7 and by cyclization of glutamate at residues 3 and 11. Pyroglutamate-containing isoforms at position 3 [pGlu 3 ]AS3-40/42] represent the prominent forms - approximately 50 % of the total Ap amount - of the N-truncated 4 species in senile plaques (Mori, H. et al. 1992 J Biol Chem 267, 17082-17086, Saido, T. C. et al. 1995 Neuron 14, 457-466; Russo, C. et al. 1997 FEBS Lett 409, 411-416; Tekirian, T. L. et al. 1998 J Neuropathol Exp Neurol 57, 76-94; Geddes, J. W. et al. 1999 Neurobiol Ag'ng 20, 75-79; Harigaya, Y. et al. 2000 Siochem Biophys Res Commun 276, 422427) and they are also present in pre-amyloid lesions (Lalowski, M. et al. 1996 J Biol Chem 271, 33623-33631). The accumulation of ApN3(pE) peptides is likely due to the structural modification that enhances aggregation and confers resistance to most amino-peptidases (Saido, T. C. et al. 1995 Neuron 14, 457-466 ; Tekirian, T. L. et al. 1999 J Neurochem 73, 1584-1589). This evidence provides clues for a pivotal role of ApN3(pE) peptides in AD pathogenesis. However, relatively little is known about their neurotoxicity and aggregation properties (He, W. and Barrow, C. J. 1999 Biochemistry 38, 10871-10877; Tekirian, T. L. et al. 1999 J Neurochem 73, 1584-1589). Moreover, the action of these isoforms on glial cells and the glial response to these peptides are completely unknown, although activated glia is strictly associated to senile plaques and might actively contribute to the accumulation of amyloid deposits. In recent studies the toxicity, aggregation properties and catabolism of A01-42, AD1-40, [pGIu 3 ]A03-42 and [pGlu 3 ]A03-40 peptides were investigated in neuronal and glial cell cultures, and it was shown that pyroglutamate modification exacerbates the toxic properties of AP-peptides and also inhibits their degradation by cultured astrocytes. Shirotani et al. investigated the generation of [pGlu]Ap peptides in primary cortical neurons infected by Sindbis virus in vitro. They constructed amyloid precursor protein complementary DNAs, which encoded a potential precursor for [pGlu 3 }AO by amino acid substitution and deletion. For one artificial precursor starting with a N-terminal glutamine residue instead of glutamate in the natural precursor, a spontaneous conversion or an enzymatic conversion by glutaminyl cyclase to pyroglutamate was suggested. The cyclization mechanism of N-terminal glutamate at position 3 in the natural precursor of [pGlu 3 ]A was not determined in vivo (Shirotani, K., Tsubuki, S., Lee, H. J., Maruyama, K., and Saido, T. C. (2002) Neurosci Lett 327, 25-28) Dipeptidyl peptidase IV (DP IV) is a post-proline (to a lesser extent post-alanine, post-serine or post.-glycine) cleaving serine protease found in various tissues of the 5 body including kidney, liver, and intestine and cleaves N-terminal dipeptides from a peptide chain. Recently it was shown that DP IV plays an important role in neuropeptide metabolism, T-cell activation, attachment of cancer cells to the endothelium and the entry of HIV into lymphoid cells. See therefore WO 02/34242, WO 02/34243, WO 03/002595 and WO 03/002596. It is known that DP IV inhibitors may be useful for the treatment of impaired glucose tolerance and diabetes mellitus (International Patent Application, Publication Number WO 99/61431, Pederson, R. A. et al. 1998 Diabetes 47,1253-1258 and Pauly, R. P. et al. 1999 Metabolism 48, 385-389). In particular WO 99/61431 discloses DP IV inhibitors comprising an amino acid residue and a thiazolidine or pyrrolidine group, and salts thereof, especially L-threo-isoleucyl thiazolidine, L-allo-isoleucyl thiazolidine, L-threo-isoleucyl pyrrolidine, L-alo-isoleucyl thiazolidine, L-allo-isoleucyl pyrrolidine, and salts thereof. Further examples of low molecular weight dipeptidyl peptidase IV inhibitors are agents such as ietrahydroisoquinolin-3-carboxamide derivatives, N-substituted 2 cyanopyroles and -pyrrolidines, N-(N'-substituted glycyl)-2-cyanopyrrolidines,
N
(substituted glycyll)-thiazolidines, N-(substituted glycyl)-4-cyanothiazolidines, amino acyl-borono-prolyl -inhibitors, cyclopropyl-f used pyrrolidines and heterocyclic compounds. Inhibitors of dipeptidyl peptidase IV are described in US 6,380,398, US 6,011,155; US 6,107,317; US 6,110,949; US 6,124,305; US 6,172,081; WO 95/15309, WO 99/61431, WO 99/67278, WO 99/67279, DE 198 34 591, WO 97/40832, DE 196 16 486 C 2, WO 98/19998, WO 00/07617, WO 99/38501, WO 99/46272, WO 99/38501, WO 01/68603, WO 01/40180, WO 01/81337, WO 01/81304, WO 01/55105, WO 02/02560 and WO 02/14271, WO 02/04610, WO 02/051836, WO 02/068420, WO 02/076450; WO 02/083128, WO 02/38541, WO 03/000180, WO 03/000181, WO 03/000250, WO 03/002530, WO 03/002531, WO 03/002553, WO 03/002593, WO 031004496, WO 03/024942 and WO 03/024965, the teachings of which are herein incorporated by reference in their entirety, especially concerning these inhibitors, their definition, uses and their production.
6 Summary of the Invention The present invention provides novel physiological substrates of 0C in mammals, A03-40/42, [Gin 3 tA-40/42, [Glu')AD11-40/42, [GIn'')Ap11-40/42, [Gln']Gastrin, [GIn']Neurotensin, [Gln')FPP, [Gln]CCL 2, [GIn 1 ]CCL 7, [Gln']CCL 8, [GIn']CCL 16, [Gln']CCL 18, {Gln']Fractalkine, [Gln']Orexin A, [GIn 3 ]glucagon3-29 and [GIn ]substance P5-11 and the use of effectors of OC and pharmaceutical compositions comprising effectors of QC for the treatment of conditions that can be treated by modulation of QC activity. it was shown by inhibition studies that human QC is a metal-dependent transferase. QC apoenzyme could be reactivated most efficiently by zinc ions, and the metal binding motif of zinc-dependent aminopeptidases is also present in human QC. Compounds interacting with the active-site bound metal are potent inhibitors. Unexpectedly, it was shown that recombinant human QOC as well as QC-activity from brain extracts catalyze both, the N-terminal glutaminyl as well as glutamate cyclization. Most striking is the finding, that cyclase-catalyzed Glu'-conversion is favored around )H 6.0 while GIn'-conversion to pGlu-derivatives occurs with a pH optimum of around 8.0. Since the formation of pGlu-AO-related peptides can be suppressed by inhibition of recombinant human OC and OC-activity from pig pituitary extracts, the enzyme 0C is a target in drug development for treatment of Alzheimer's disease. By administering effectors of QC activity to a mammal it can be possible to prevent or alleviate or treat conditions selected from Alzheimer's disease, Down Syndrome, ulcer disease and gastric cancer with or w/o Heliobacter pylori infections, pathogenic psychotic conditions, schizophrenia, infertility, neoplasia, inflammatory host responses, cancer, psoriasis, rheumatoid arthritis, atherosclerosis, impaired humoral and cell-mediated immune responses, leukocyte adhesion and migration processes in the endothelium, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance and impaired regulation of body fluids.
7 Further, by administration of effectors of OC activity to a mammal it can be possible to stimulate gastrointestinal tract cell proliferation, preferably proliferation of gastric mucosal cells, epithelial cells, acute acid secretion and the differentiation of acid producing parietal cells and histamine-secreting enterochromaff in-like cells. Furthermore, by administration of effectors of QC activity to a mammal it can be possible to suppress the proliferation of myeloid progenitor cells. In addition, administration of OC inhibitors can lead to suppression of male fertility. In a preferred embodiment, the present invention provides the use of effectors of QC activity in combination with inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and/or DP IV-activity. The present invention provides pharmaceutical compositions for parenteral, enteral or oral administration, comprising at least one effector of QC optionally in combination with customary carriers and/or excipients; or comprising at least one effector of QC in combination with at least one DP IV-inhibitor, optionally in combination with customary carriers and/or excipients. Screening methods are also provided for the identification and selection of effectors of OC. Brief description of the drawings Further understanding of these and other aspects of the present invention will be had by reference to the figures wherein: 8 Figure 1 shows progress curves of the cyclization of H-Gin-Ala-OH, catalyzed by human QOC, monitoring the decrease in absorbance at 340 nm. The samples contained 0.3 mM NADH/H+, 14 mM a-Ketoglutaric acid, 30 U/ml glutamic dehydrogenase arid 1 mM H-Gin-Ala-OH. From curve A-D, varying concentrations of QC were applied: A, 10 mU/mi, B, 5 mU/mi, C, 2.5 mU/mI. In case of curve D, QC was omitted. A linear relationship was obtained between the QC concentration and the observed activity (inset). Figure 2 shows the pH dependence of human and papaya (inset) QC, determined under first-order rate conditions using Gln-#NA as substrate. In case of human 0C, a buffer system providing a constant ionic strength according to Ellis and Morrison was used, consisting of 25 mM MES, 25 mM acetic acid and 50 mM Tris (Ellis, K. J. and Morrison, J. F. 1982 Methods Enzymol. 87, 405-426). Due to a slightly inhibiting effect of Tris, papaya 0C was investigated using a 50 mM Mops buffer. The ionic strength was adjusted to 0.05 M by addition of NaCl. The rate profiles were evaluated by fitting to a model that is based on dissociating groups. In case of papaya QC, a pKa of 7.13 ±0.03 was obtained by fitting of the data to a single dissociation model. Figure 3 shows the effect of the pH on the stability of the QOC from Papaya latex and human QC. An enzyme stock solution was diluted 20-fold in 0.1 M buffer of various pH values (pH 4-7 sodium citrate, pH 7-10 sodium phosphate). Enzyme solutions were incubated at 30 *C for 30 min and subsequently enzymatic activity was analyzed according to the standard protocol. Figure 4 shows the comparison of the specificity constant k 0 a/Km for a set of substrates containing glutamate in the second amino acid position. Whereas an increase in specificity of human 0C was detected from the di- to the tetrapeptides, no change was observed in case of papaya QC. The data presented here is a replot of the parameters given in Table 3. Figure 5 shows the formation of pGlu-Lys(pGlu)-Arg-Leu-Ala-NH2 from H-GIn Lys(GIn)-Arg-Leu-Ala-NH 2 , catalyzed by human QC. Substrate conversion is 9 monitored by a time-dependent change in the m/z ratio due to the expulsion of ammonia. The sample composition was 0.5 mM substrate, 38 nM OC in 40 mM Tris/HCI, pH 7.7. At the times indicated, samples were removed from the assay tube, mixed with matrix solution (1:1 v/v) and subsequently the mass spectra recorded. A very similar dependence was observed in case of papaya QC. Figure 6 shows the formation of pGlu-Phe-Lys-Ala-Glu-NH 2 from H-Gln(NMe)-Phe Lys-Ala-Glu-NH 2 catalyzed by papaya QC. Substrate conversion is monitored by a time-dependent change in the m/z ratio due to the expulsion of methylamine. The sample composition was 0.5 mM substrate, 0.65 pM papaya OC in 40 mM Tris/HCI, pH 7.7. At the times indicated, samples were removed from the assay tube, mixed with matrix solution (1:1 v/v) and subsequently the mass spectra recorded. No substrate conversion was observed in samples without papaya QC or by applying up to 1.5 pM human OC to the substrate (not shown). Figure 7 shows the formation of [GIn 3 ]-AP3-11 from [Gin 3 ]A$1 -11 catalysed by DPIV. At the times indicated, samples were removed, from the assay tube, mixed with matrix solution (1:1 v/v) and subsequently the mass spectra recorded. Figure 8 shows the prevention of the cleavage of [GIn 3 ]AP1-1 1 by the DP IV-inhibitor Val-Pyrrolidide (Val-Pyrr). At the times indicated, samples were removed from the assay tube, mixed with matrix solution (1:1 v/v) and subsequently the mass spectra recorded. Figure 9 shows the formation of [pGlu 3 ]AO3-11 from [GIn 3 )A p3-11 catalyzed by QC. At the times indicated, samples were removed from the assay tube, mixed with matrix solution (1:1 v/v) and subsequently the mass spectra recorded. Figure 10 shows the inhibition of the formation of [pGlu 3 ]A3-11 from [GIn 3 ]A03-1 I by the QC-inhibitor 1,10-phenanthroline. At the times indicated from the assay tube, samples were removed, mixed with matrix solution (1:1 v/v) and subsequently the mass spectra recorded.
10 Figure 11 shows the formation of [pGlus)Ap3-11 from [Gln 3 }A$1-11 after consecutive catalysis by DP IV and 0C. At the times indicated, samples were removed from the assay tube, mixed with matrix solution (1:1 v/v) and subsequently the mass spectra recorded. Figure 12 shows the inhibition of [pGlu 3 ]As3-1 1 formation from [Gin 3 ]AP1-1 1 by the QC-inhibitor 1,10-phenanthroline in the presence of catalytically active DP IV and OC. At the times indicated, samples were removed from the assay tube, mixed with matrix solution (1:1 v/v) and subsequently the mass spectra recorded. Figure 13 shows the reduction of [pGlu 3 ]AP3-11 formation from [Gin 3 ]Ap1-11 by the DP IV-inhibitor Val-Pyrr in the presence of catalytically active DP IV and QC. At the times indicated, samples were removed from the assay mixture, mixed with matrix solution (1:1 v/v) and subsequently the mass spectra recorded. Figure 14 shows the formation of [pGlu 3 ]AD-peptide3-11 from [Gin 3 )AD1-11 after consecutive catalysis by aminopeptidase(s) and OC that are present in porcine pituitary homogenate. At the times indicated, samples were removed from the assay tube, mixed with matrix solution (1:1 v/v) and subsequently the mass spectra recorded. Figure 15 A and B show Mass spectra of Ap3-11a and As3-21a incubated with recombinant human 0C, that was boiled for 10 min before use. C and D show Mass spectra of A03-11 and Ap3-21a in presence of active human QC resulting in the formation of [pGlua 3 }A53-1 1a and [pGlu 3 }AP3-21a, respectively. E and F show Mass spectra of AP3-11 a and Ap3-21 a in presence of active 0C and 5 mM Benzimidazole suppressing the formation of [pGlus3formation. Figure 16 shows reaction rates of papaya QC- catalyzed Glu-fNA-conversion plotted against the substrate concentration. The initial rates were measured in 0.1 M pyrophosphate bulfer, pH 6.1 (squares), 0.1 M phosphate buffer, pH 7.5 (circles) and 11 0.1 M borate buffer, pH 8.5 (triangles). The kinetic parameters were as follows: Km= 1.13 ±0.07 mM, kct= 1.13 ±0.04 min" (pH 6.1); Km= 1.45 ±0.03 mM, ka,= 0.92 ±0.01 min- (pH 7.5); Km= 1.76 ±0.06 mM, koat= 0.56 ±0.01 min" (pH 8.5). Figure 17 shows the pH-dependence of the conversion of Gln-PNA (circles) and Glu #NA (squares), determined under first-order rate-law conditions (S<<Km). Substrate concentration was 0.01 mM and 0.25 mM, respectively. For both determinations, a three-component buffer system was applied consisting of 0.05 M acetic acid, 0.05 M pyrophosphoric acid and 0.05 M Tricine. All buffers were adjusted to equal conductivity by addition of NaCl, in order to avoid differences in ionic strength. The data were fitted to equations that account for two dissociating groups revealing pva values of 6.91 ±0.02 and 9.5 ±0.1 for Gln-#NA and 4.6 ±0.1 and 7.55 ±0.02 for Glu #NA. The pKa-values of the respective substrate amino groups, determined by titration, were 6.97 ±0.01 (Gin-#NA) and 7.57 ±0.05 (Glu-#NA). All determinations were carried out at 30 *C. Figure 18 shows progress curves of human QC-catalyzed cyclization of H-Gln-AMC in presence of imidazole, dipicolinic acid and in absence of an inhibitory compound. The hyperbolic shape of the curve in presence of dipicolinic acid indicates metal ion remove from the active site of QC. Figure 19 shows the time-dependent inactivation of QC by the heterocyclic chelator 1,10-phenanthroline. After incubation of the QC-enzyme with the inhibitor in absence of substrate (continuous line), a reduced enzymatic activity was observed compared to samples that were not preincubated with inhibitor (dotted trace), indicating metal ion remove from the active site of QC. Figure 20 shows the reactivation of human QC with monovalent- and divalent metal ions. QC was inactivated by addition of 2 mM dipicolinic acid in 50 mM Bis-Ths, pH 6.8. Subsequently, the enzyme was subjected to dialysis against 50 mM Bis-Tris, pH 6.8, containing 1.0 mM EDTA. Reactivation of the enzymes was achieved by incubation of the inactivated enzyme sample with metal ions at a concentration of 0.5 mM, In presence of 0.5 mM EDTA in order to avoid an unspecific reactivation by 12 traces of metal ions present in buffer solutions. Controls are given by enzyme samples that were not inactivated, but also dialyzed against EDTA solution as the inactivated enzyme (+EDTA) and enzyme samples that were dialyzed against buffer solutions without added EDTA (-EDTA). Figure 21 Sequence alignment of human QC (hQC) and other M28 family members of the metallopeptidase Clan MH. Multiple sequence alignment was performed using ClustalW at ch.EMBnet.org with default settings. The conservation of the .zinc-ion ligating residues is shown for human QC (hQC; GenBank X71125), the Zn-dependent aminopeptidase fiom Streptomyces griseus (SGAP; Swiss-Prot P80561), and within the N-acetylated-alpha-linked acidic dipeptidase (NAALADase I) domain (residues 274 587) of the human Glutamate carboxypeptidase II (hGCP II; Swiss-Prot Q04609). The amino acids involved in metal binding are typed in bold and underlined. In case of human QC, these residues are the putative counterparts to the peptidases. Figure 22: A shows the mass spectra of human [Gln 3 ]APl-1la incubated with recombinant human QC and DPIV resulting in generation of [pGlu]AP3-1 Ia (asterisk). B mass spectra of human [Gln 3 ]AP3 1-11 a incubated with recombinant human QC and DPIV in presence of the DPIV-inhibitor Val-Pyrr. C mass spectra of human [Gln 3 ]AP31- Ila incubated with recombinant human QC and DPIV in presence of the QC-inhibitor 1-(3 (IH-imidazol-1-ylipropyl)-3-(3,4-dimethoxyphenyl)thiourea D mass spectra of human [Gln 3 ]AP 1-1 la incubated with recombinant human QC and DPIV in presence of the QC inhibitor 1-(3-(I I-imidazol-1-yl)propyl)-3-(3, 4 -dimethoxyphenyl)thiourea and DPIV inhibitor Val-Pyrr. Due to inhibition by either DPIV or QC, formation of [pGluAP]3- 11 a is suppressed. Use of the combination of 1-( 3 -(IH-imidazol-1-yl)propyl)-3-(3,4 dimethoxyphenyl)thiourea and Val-Pyrr inhibitors was most efficient because [pGluAP]3 1 a-formation was negligible, as shown in D. Peptide Sequences: The peptides mentioned and used herein have the following sequences: AP1 -42: Asp-Ala-Glu-Phe-Arg-His-Asp-S er-Gy-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe- 1 2a Ph - l- l- s)V lGySrA nL sG y-l-l-l- l-e - e-a- l- l-a Val-Ile-Ala AfrI-40: Val AP3-42: Glu-Phe-Arg-His-ApSrGyTrGu a-i-i-l-y-LuVlPePeAa Glu-Asp-Val-Gly-S er-Asn-Lys-GI y-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-GyVa-Valne Ala AP3340: Glu-Asp-Val-Gly -Ser-Asn-Lys-GyAaIe-IleGyLeuMetVaI GlyoGlyrVaval AJpl-ila: Asp-Ala-Glu-Phe -Arg-I-lis-Asp-Ser-Gly-Tyr-Glu-NH 2 13 Ap3-1 ia: Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-NH2 Ap1-21a: Asp-Ala-Glu-Phe-Arg-His-Asp-Se r-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe Phe-Ala-NH2 Ap3-21 a: Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gin-Lys-Leu-Val-Phe-Phe-Ala
NH
2 Gin 3 -AP3-40: Gin-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gin-Lys-Leu-Val-Phe-Phe-Ala Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-ile-lie-Gly-Leu-Met-Val-Gly-Gly-Val-Val Gin 3 -Ap3-21a: Gln-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala
NH
2 Gin 3 -A1-11 a: Asp-Ala-Gln-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-NH2 Gin 3 -AP3-I a: Gln-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-NH2 Detailed description of the Invention The present invention provides effectors of glutaminyl cyclase (0C) for a) the treatment of diseases in mammals that can be treated by modulation of OC activity in vivo and/or b) the modulation of physiological processes based on the action of pGlu containing peptides caused by modulation of OC activity. Furthermore, the present invention provides compounds for the inhibition of glutaminyl cyclase (OC, EC 2.3.2.5) and/or 0C-like enzymes in a mammal and the use of inhibitors of 0C activity for the treatment of pathological conditions related to QC activity. The present invention also provides a new method for the treatment of Alzheimer's disease and Down Syndrome. The N-termini of amyloid p-peptides deposited in Alzheimer's disease and Down syndrome brain bear pyroglutamic acid. The pGlu 14 formation is an important event in the development and progression in the disease, since the modified amyloid 5-peptides show an enhanced tendency to p-amyloid aggregation and toxicity, likely worsening the onset and progression of the disease. (Russo, C. et al. 2002 J Neurochem 82,1480-1489). In contrast, in the natural Ap-peptides (3-40/42), glutamic acid is present as an N terminal amino acid. There is no enzymic conversion of Glu to pGlu known to date. Moreover, spontaneous cyclization of Glu-peptides to pGlu-peptides has not been observed as yet. Therefore one aspect of the present invention was to determine the role of OC in Alzheimer's disease and Down Syndrome. This aspect was addressed by the synthesis of A03-11 and A01 -11, containing the amino acid glutamine instead of glutamic acid at position three, the determination of the substrate characteristics of these modified amyloid P-peptides against QC, DP IV and DP IV-like enzymes and aminopeptidases and the use of inhibitors of QC to prevent the formation of pGlu from a N-terminal glutaminyl residue of the amyloid P-derived peptides 1-11 and 3 11. The results are shown in example 8. The applied method is described in example 3. To date, there are no hints indicating an involvement of QC in the progression of the disease, because glutamic acid is the N-terminal amino acid in AP (3-40/42, or 11 40/42). But, 0C is the only known enzyme capable of forming pGlu at the N-terminus of peptides. Other aspects of the present invention concern the following findings and discoveries: a) In a side reaction, QC catalyzes the cyclization of glutamic acid to pyroglutamic acid at very low rates, b) Glutamic acid of APP or its subsequently formed amyloid-#-peptides is converted into glutamine post-translationally by an unknown enzymatic activity and in a second step, QC catalyzes the cyclization of glutamine into pyroglutamic acid after processing of the amyloid p-peptide N-terminus, 15 c) Glutamic acid is converted into glutamine post-translationally by a chemical catalysis or autocatalysis and subsequently, 0C catalyzes the cyclization of glutamine to pyroglutamic acid after processing of the amyloid $-peptide N-terminus, d) There are mutations in the APP gene, which encode the amyloid 0 protein, leading to Gin instead of Glu in position 3. After translation arid processing of the N-terminus, 0C catalyzes the cyclization of glutamine to pyroglutamic acid, e) Glutamine is incorporated into the nascent peptide chain of APP, due to a malfunction of an unknown enzymatic activity and subsequently, QC catalyzes the cyclization of N-terminally glutamine to pyroglutamic acid after processing of the amyloid O-peptide N terminus. QC is involved in the critical step in all five cases listed above, namely the formation of pyroglutamic acid that favors the aggregation of amyloid 0-peptides. Thus, an inhibition of 0C leads to a prevention of the precipitation of the plaque-forming As3 40/41/43 or A0111-40/41/43, causing the onset and progression of Alzheimer's disease and Down Syndrome, independently of the mechanism by which cyclization occurs. Glutamate is found in positions 3, 11 and 22 of the amyloid D-peptide. Among them the mutation from glutamic acid (E) to glutamine (Q) in position 22 (corresponding to amyloid precursor protein APP 693, Swissprot P05067) has been described as the so called Dutch type cerebroarterial amyloidosis mutation. The 0-amyloid peptides with a pyroglutamic acid residue in position 3, 11 and/or 22 have been described to be more cytotoxic and hydrophobic than A51-40/42/43 (Saido T.C. 2000 Medical Hypotheses 54(3): 427-429). The multiple N-terminal variations can be generated by the P--secretase enzyme 0 site amyloid precursor protein-cleaving enzyme (BACE) at different sites (Huse J.T. et al. 2002 J. Eiol. Chem. 277 (18): 16278-16284), and/or by aminopeptidase 16 processing. In all cases, cyclization can take place according to a)-e) as described above. So far, there was no experimental evidence supporting the enzymatic conversion of Glul-peptides into pGlu-peptides by an unknown glutamyl cyclase (EC) corresponding to pathway a) (Garden, R. W., Moroz, T. P., Gleeson, J. M., Floyd, P. D., Li, L. J., Rubakhin, S. S., and Sweedler, J. V. (1999) J Neurochem 72, 676-681; Hosoda R. et al. (1998) J Neuropathol Exp Neurol. 57, 1089-1095). To date, no such enzyme activity has been identified, capable to cyclize Glul-peptides which are protonated N-terminally and possess a negatively charged Glu' y-carboxylate moiety under mildly alkaline pH-conditions. QC-activity against GIn-substrates is dramatically reduced below pH 7.0. In contrast, it appears that GIl'-conversion can occur at acidic reaction conditions (lwatsubo, T., Saido, T. C., Mann, D. M., Lee, V. M., and Trojanowski, J. Q. (1996) Am J Pathol 149, 1823-1830; Russo, C., Saido, T. C., DeBusk, L. M., Tabaton, M., Gambetti, P., and Teller, J. K. (1977) FEBS Lett 409, 411-416; Russo, C., Salis, S., Dolcini, V., Venezia, V., Song, X. H., Teller, J. K., and Schettini, G. (2001) Neurobiol Dis 8, 173 180; Tekirian, T. L., Saido, T. C., Markesbery, W. R., Russell, M. J., Wekstein, D. R., Patel, E., and Geddes, J. W. (1998) J Neuropathol Exp Neurol. 57, 76-94; Russo, C., Violani, E., Salis, S., Venezia, V., Dolcini, V., Damonte, G., Benatti, U., DArrigo, C., Patrone, E., Carlo, P., and Schettini, G. (2002) J Neurochem 82, 1480-1489; Hosoda, R., Saido, T. C., Otvos, L., Jr., Arai, T., Mann, D. M., Lee, V. M., Trojanowski, J. Q., and lwatsubo, T. (1998) J Neuropathol Exp Neurol. 57, 1089 1095; Garden, R. W., Moroz, T. P., Gleeson, J. M., Floyd, P. D., Li, L. J., Rubakhin, S. S., and Sweedler, J. V. (1999) J Neurochem 72, 676-681). According to the present invention it was investigated whether QC is able to recognize and to turnover amyloid-p derived peptides under mild acidic conditions. Therefore, the peptides [Gln 3 ]Ap1-11 a, Ap3-1 1a, [Gln]A03-1 1a, A03-21a, [Gln 3 )AP3 21 a and [Gin 3 }Ap3-40 as potential substrates of the enzyme were synthesized and investigated. These sequences were chosen for mimicking natural N-terminally and 17 C-terminally truncated [Glu 3 ]AP peptides and [Gin 3 ]Ap peptides which could occur due to posttranslational Glu-amidation. In the present invention it was shown that papaya and human QC catalyze both glutaminyl and glutamyl cyclization. Apparently, the primary physiological function of OC is to finish hormone maturation in endocrine cells by glutamine cyclization prior or during the hormone secretion process. Such secretory vesicles are known to be acidic in pH. Thus, a side activity of the enzyme in the narrow pH-range from 5.0 to 7.0 could be its newly discovered glutamyl cyclase activity transforming also Glu-AD peptides. However, due to the much slower occurring Glu-cyclization compared to Gin-conversion, it is questionable whether the glutamyl cyclization plays a significant physiological role. In the pathology of neurodegenerative disorders, however, the glutamyl cyclization is of relevance. Investigating the pH-dependency of this enzymatic reaction, we found that the unprotonated N-terminus was essential for the cyclization of Gin'-peptides and accordingly that the pKe-value of the substrate was identical to the pK-value for QC catalysis (see Figure 17). Thus, C stabilizes the intramolecular nucleophilic attack of the unprotonated a-amino moiety on the y-carbonyl carbon electrophilicaly activated by amidation (Scheme 1). In contrast to the monovalent charge present on N-terminal glutamine containing peptides, the N-terminal Glu-residue in Glu-containing peptides is predominantly bivalently charged around neutral pH. Glutamate exhibits pK 8 -values of about 4.2 and 7.5 for the y-carboxylic and for the a-amino moiety, respectively. I.e. at neutral pH and above, although the a-amino nitrogen is in part or fully unprotonated and nucleophilic, the y-carboxylic group is unprotonated, and so exercising no electrophilic carbonyl activity. Hence, intramolecular cyclization is impossible. However, in the pH-range of about 5.2-6.5, between their respective pKevalues, the two functional groups are present both in non-ionized forms, in concentrations of about 1-10% (-NH:a) or 10-1% (-COOH) of total N-terminal Glu-containing peptide. As a result, over a mildly acidic pH-range species of N-terminal Glu-peptides are present which carry both groups uncharged, and, therefore, it is possible that OC could stabilize the intermediate of intramolecular cyclization to pGlu-peptide. I.e. if the y- 18 carboxylic group is protonated, the carbonyl carbon is electrophilic enough to allow nucleophilic attack by the unprotonated a-amino group. At this pH the hydroxyl ion functions as a leaving group (Scheme 3). These assumptions are corroborated by the pH-dependence data obtained for the QOC catalyzed conversion of Glu-#NA (see example 11). In contrast to glutamine conversion of Gln-#3NA by CC, the pH-optimum of catalysis shifts to the acidic range around pH 6.0, i.e. the pH-range, in which substrate molecule species are simultaneously abundant carrying a protonated y carboxyl and unprotonated a-amino group. Furthermore, the kinetically determined pK,-value of 7.55 ±0.02 is in excellent agreement with that of the a-amino group of Glu-#NA, determined by titration (7.57 ±0.05). Physiologically, a pH 6.0 the second-order rate constant (or specificity constant, km/Km) of the QC-catalyzed glutamate cyclization might be in the range of 8,000fold slower than the one for glutamine cyclization (Figure 17). However, the nonenzymatic turnover of both model substrates Glu-#NA and Gln-PNA is negligible, being conform with the observed negligible pGlu-peptide formation in the present invention. Hence, for the pGlu-formation by OC an acceleration of at least 108 can be estimated from the ratio of the enzymatic versus non-enzymatic rate constants (comparing the second-order rate constants for the enzyme catalysis with the respective nonenzymatic cyclization first-order rate constants the catalytic proficiency factor is 101- 1011 M' for the GIn- and the Glu-conversion, respectively). The conclusion from these data is, that in vivo only an enzymatic path resulting pGlu-formations seems conceivable. Since OC is highly abundant in the brain and taking into account the high turnover rate of 0.9 min' recently found for the maturation of 30 pM of (Gln-)TRH-like peptide (Prokai, L., Prokai-Tatrai, K., Ouyang, X., Kim, H. S., Wu, W. M., Zharikova, A., and Bodor, N. (1999) J Med Chem 42, 4563-4571), one can predict a cyclization half-life of about 100 hours for an appropriate glutamate-substrate, similar reaction conditions provided. Moreover, given compartmentalization and localization of brain QC/EC in the secretory pathway, the actual in vivo enzyme and substrate concentrations and reaction conditions might be even more favorable for the enzymatic cyclization in the intact cell. And, if N-terminal Glu is transformed to GIn a much more rapid pGlu- 19 formation mediated by 0C could be expected. In vitro, both reactions were suppressed by applying inhibitors of QC/EC-activity (Figures 9, 10 and 15). In summary, the present invention shows that human OC, which is highly abundant in the brain, is a likely catalyst to the formation of the amyloidogenic pGlu-Ap peptides from Glu-Ap and Gln-AD precursors which make up more than 50% of the plaque deposits found in Alzheimer's Disease. These findings identify QC/EC as a player in senile plaque formation and thus as a novel drug target in the treatment of Alzheimer's Disease. In a second embodiment of the present invention, it was found that amyloid @ derived peptides are a substrate of dipeptidyl peptidase IV (DP IV) or DP IV-like enzymes, preferably dipeptidyl peptidase I (DPIlI). DP IV, DP 11 or other OP IV-like enzymes release a dipeptide from the N-terminus of the modified amyloid p-peptide (1-11) generating amyloid 0-peptide (3-11) with glutamine as the N-terminal amino acid residue. The results are shown in example 8. Prior to cleavage ty DP 11, DPIV or other DP IV-like enzymes, the peptide bond between aspartic acid (residue 1 of amyloid P-peptide) and alanine (residue 2 of amyloid p-peptide) may be isomerised yielding an isoaspartyl residue as described in the literature (Kuo, Y.-M., Emmerling, M. R., Woods, A. S., Cotter, R. J., Roher, A. E. (1997) BBRC 237, 188-191; Shimizu, T., Watanabe, A., Ogawara, M., Mori, H. and Shirasawa, T. (2000) Arch. Biochem. Biophys. 381, 225-234). These isoaspartyl residues render the amyloid 0-peptide resistant against aminopeptidase degradation and consequently the core plaques contain high amounts of isoAspl-amyloid p-peptides, which suggests a reduced turnover at the N terminus. However, in the present invention it is demonstrated for the first time, that the N terminal dipeptide H-isoAspl-Ala 2 -OH can be released by dipeptidyl peptidases especially under acidic conditions. Furthermore, it was shown that isomerization can precede also cleavage by S-secretase, and that isomerization may accelerate proteolytic processing, thus leading to liberation of an N-terminal isoaspartyl bond of isoAsp 1 -amyloid p-peptides which subsequently is subject to turnover by DP 11, DPIV or DP IV-like enzymes (Momand, J. and Clarke, S. (1987) Biochemistry 26, 7798- 20 7805; Kuo, Y.-M., Emmerling, M. R., Woods, A. S., Cotter, R. J., Roher, A. E. (1997) BBRC 237, 188-191). Accordingly, inhibition of isoaspartyl formation may lead to the reduction of cleavage by p-secretase and, in turn, to a reduced formation of amyloid p-peptides. In addition, blockage of the isoAspl-amyloid P-peptide turnover by inhibition of DP 11, DP1V or DP IV-like enzymes would prevent the exposure of [Glu 3 sAp to QC/EC-catalyzed formation of [pGlu 3 ]Ap. In a third embodiment of the present invention, a combination of inhibitors of DP IV activity and of inhibitors of 0C can be used for the treatment of Alzheimer's disease and Down Syndrome. The combined effect of DP IV and/or DP IV-like enzymes and of 0C is illustrated as follows: a) OF IV and/or DP IV-like enzymes cleave As1-40/42, a dipeptide comprising H-Asp-Ala-OH and A03-40/42 are released, b) In a side reaction, QC catalyzes the cyclization of glutamic acid to pyroglutamic acid at very low rates, c) Glutamic acid is converted into glutamine at the N-terminus post translationally by an unknown enzymatic activity and subsequently, QC catalyzes the cyclization of glutamine into pyroglutamic acid after processing of the amyloid p-peptide N-terminus, d) Glutamic acid is converted into glutamine post-translationally by a chemical catalysis or autocatalysis and in a second step, QC catalyzes the cyclization of glutamine into pyroglutamic acid after processing of the amyloid D-peptide N-terminus, e) There are mutations in the APP gene, which encode the amyloid p protein, leading to GIn instead of Glu in position 3 of AD, After translation and processing of the N-terminus, 0C catalyzes the cyclization of glutamine to pyroglutamic acid, f) Glutamine is incorporated into the nascent peptide chain of APP, due to a malfunction of an unknown enzymatic activity and subsequently, 0C catalyzes the cyclization of N-terminally glutamine 21 to pyroglutamic acid after processing of the amyloid 0-peptide N terminus, The N-terminal Gin-exposure to OC-activity can be also triggered by different peptidase activities. Aminopeptidases can remove sequentially Asp and Ala from the N-terminus of A01-40/41/43, thus unmasking amino acid three that is prone to cyclization. Dipeptidyl peptidases, such as DP 1, DP 11, DP IV, DP 8, DP 9 and DP 10, remove the dipeptide Asp-Ala in one step. Hence, inhibition of aminopeptidase- or dipeptidylpeptidase-activity is useful to prevent the formation of A03-40/41/43. The combined effect of inhibitors of DP IV and/or DP IV-like enzymes and of activity lowering effectors of QOC is illustrated in the following way: a) The inhibitors of DP IV and/or DP IV-like enzymes inhibit the conversion of API-40/42 to Ap3-40/42. b) An N-terminal exposure of glutamic acid is thereby prevented and no conversion to glutamine, either by enzymatic or by chemical catalysis, subsequently leading to pyroglutamic acid formation, is possible. c) Inhibitors of QC prevent in addition the formation pyroglutamic acid from any residual modified AP3-40/42 molecules and those modified A 3-40/42 molecules, which are generated by mutations of the APP gene. Within the present invention, a similar combined action of DP IV or DP IV-like enzymes and QC was demonstrated for further peptide hormones, such as glucagon, CC chemokines and substance P. Glucagon is a 29-amino acid polypeptide released from pancreatic islet alpha-cells that acts to maintain euglycemia by stimulating hepatic glycogenolysis and gluconeogenesis. Despite its importance, there remains controversy about the mechanisms responsible for glucagon clearance in the body. Pospisilik et al.
22 assessed the enzymatic metabolism of glucagon using sensitive mass spectrometric techniques to identify the molecular products. Incubation of glucagon with purified porcine dipeptidyl peptidase IV (DP IV) yielded sequential production of glucagon3 29 and glucagon5-29. In human serum, degradation to glucagon3-29 was rapidly followed by N-terminal cyclization of glucagon, preventing further DP IV-mediated hydrolysis. Bioassay of glucagon, following incubation with purified DP IV or normal rat serum demonstrated a significant loss of hyperglycemic activity, while a similar incubation in DP IV-deficient rat serum did not show any loss of glucagon bioactivity. Degradation, monitored by mass spectrometry and bioassay, was blocked by the specific DP IV inhibitor, isoleucyl thiazolidine. These results identify DP IV as a primary enzyme involved in the degradation and inactivation of glucagon. These findings have important implications for the determination of glucagon levels in human plasma (Pcspisilik et al., Regul Pept 2001 Jan 12;96(3):133-41). Human Monocyte Chemotactic Protein (MCP)-2 has originally been isolated from stimulated osteosarcoma cells as a chemokine coproduced with MCP-1 and MCP-3. Von Coillie et al. (Van Coillie, E. et al. 1998 Biochemistry 37, 12672-12680) cloned a 5-end extended MCP-2 cDNA from a human testis cDNA library. It encoded a 76 residue MCP-2 protein, but differed from the reported bone marrow-derived MCP-2 cDNA sequence in codon 46, which coded for a Lys instead of a Gin. This MCP 2Lys46 variant, caused by a single nucleotide polymorphism (SNP), was biologically compared with MCP-2GIn46. The coding regions were sub-cloned into the bacterial expression vector pHEN1, and after transformation of Escherichia coli, the two MCP 2 protein variants were recovered from the periplasm. Edman degradation revealed a Gin residue at the NH 2 terminus instead of a pGlu. rMCP-2Gln46 and rMCP-2Lys46 and the NH 2 -terminal cyclic counterparts were tested on monocytic cells in calcium mobilization and chemotaxis assays. No significant difference in biological activity was observed between the rMCP-2GIn46 and rMCP-2Lys46 isoforms. However, for both MCP-2 variants the NH 2 -terminal pyroglutamate was shown to be essential for chemotaxis, but not for calcium mobilization. NH 2 -terminal truncation of rMCP-2Lys46 by the serine protease CD26/dipeptidyl peptidase IV (CD26/DPP IV) resulted in the release of the NH 2 -terminal Gin-Pro dipeptide, whereas synthetic MCP-2 with an 23 amino-terminal pGlu remained unaffected. CD26/DPP IV-clipped rMCP-2Lys46(3-76) was almost completely inactive in both chemotaxis and signaling assays. These observations indicated that the NH 2 -terminal pGlu in MCP-2 is necessary for chemotactic activity but also that it protects the protein against degradation by CD26/DPP IV (van Coillie, E.. et al. Biochemistry 1998 37, 12672-80). Within the present invention, it was determined by LC/MS-analysis that the formation of the N-terminal pyroglutamate residue determined in glucagon3-29 (Pospisilik et al., 2001), and in MCP-2 isoforms (van Coillie et al., 1998), is catalyzed by OC. In addition, it was proven by LC/MS-investigation that after N-terminal DP IV catalyzed removal of the two dipeptides Lys-Pro and Arg-Pro from substance P the remaining [GIn 5 )substanceP5-11 is transformed by OC to [pGlu 5 ]substanceP5-1 1. DP IV inhibitors are disclosed in WO 99/61431. In particular, DP IV inhibitors are disclosed comprising an amino acid residue and a thiazolidine or pyrrolidine group, and salts thereof, especially L-threo-isoleucyl thiazolidine, L-allo-isoleucyl thiazolidine, L-threo-isoleucyl pyrrolidine, L-allo-isoleucyl thiazolidine, L-allo-isoleucyl pyrrolidine, and salts thereof. Further examples of low molecular weight dipeptidyl peptidase IV inhibitors are agents such as tetrahydroisoquinolin-3-carboxamide derivatives, N-substituted 2 cyanopyroles ard -pyrrolidines, N-(N'-substituted glycyl)-2-cyanopyrrolidines,
N
(substituted glycyl)-thiazolidines, N-(substituted glycyl)-4-cyanothiazolidines, amino acyl-borono-prolyl-inhibitors, cyclopropyl-fused pyrrolidines and heterocyclic compounds. Inhibitors of dipeptidyl peptidase IV are described in US 6,380,398, US 6,011,155; US 6,107,317; US 6,110,949; US 6,124,305; US 6,172,081; WO 95/15309, WO 99/61431, WO 99/67278, WO 99/67279, DE 198 34 591, WO 97/40832, DE 196 16 486 C 2, WO 98/19998, WO 00/07617, WO 99/38501, WO 99/46272, WO 99/38501, WO 01/68603, WO 01/40180, WO 01/81337, WO 01/81304, WO 01/55105, WO 02/02560 and WO 02/14271, WO 02/04610, WO 02/051836, WO 02/068420, WO 02/076450; WO 02/083128, WO 02/38541, WO 24 03/000180, WO 03/000181, WO 03/000250, WO 03/002530, WO 03/002531, WO 03/002553, WO 03/002593, WO 03/004496, WO 03/024942 and WO 03/024965, the teachings of which are herein incorporated by reference in their entirety, especially concerning these inhibitors, their definition, uses and their production. Preferred for the use in combination with effectors of QC are DPIV inhibitors such as NVP-D PP728A (1-[ [ [ 2-1 {5-cyanopyridin-2-yllamino]ethyi]amino]acetyll-2-cyano-(S) pyrrolidine) (Novartis) as disclosed by Hughes et al. 1999 Biochemistry 38 11597 11603, LAF-23;7 (1 -[(3-hydroxy-adamant-1 -ylamino)-acetyll-pyrrolidine-2(S) carbonitrile); disclosed by Hughes et al., Meeting of the American Diabetes Association 2002, Abstract no. 272 (Novartis), TSL-225 (tryptophyl-1,2,3,4 tetrahydroisoquinolne-3-carboxylic acid), disclosed by Yamada et al. 1998 Bioorg Med Chem Lett 8 , 1537-1540, 2-cyanopyrrolidides and 4-cyanopyrrolidides as disclosed by Aswoilh et al. 1996 Bioorg Med Chem Lett 6, , 1163-1166 and 2745 2748 , FE-999011, disclosed by Sudre et al. 2002 Diabetes 51, 1461-1469 (Ferring) and the compounds disclosed in WO 01/34594 (Guilford), employing dosages as set out in the above references. More preferred OP IV inhibitors for the use in combination with effectors of OC are dipeptide compounds in which the amino acid is preferably selected from a natural amino acid, such as, for example, leucine, valine, glutamine, glutamic acid, proline, isoleucine, asparagines and aspartic acid. The dipeptide-like compounds used according to the invention exhibit at a concentration (of dipeptide compounds) of 10 pM, a reduction in the activity of plasma dipeptidyl peptidase IV or DPIV-analogous enzyme activities of at least 10 %, especially of at least 40 %. Frequently a reduction in activity of at least 60 % or at least 70 % is also desired in vivo. Preferred compounds may also exhibit a reduction in activity of a maximum of 20 % or 30 %. Preferred dipeptide compounds are N-valyl prolyl, 0-benzoyl hydroxylamine, alanyl pyrrolidine, isoleucyl thiazolidine like L-allo-isoleucyl thiazolidine, L-threo-isoleucyl pyrrolidine and salts thereof, especially the fumaric salts, and L-allo-isoleucyl pyrrolidine and salts thereof. Especially preferred compounds are glutaminyl 25 pyrrolidine and glulaminyl thiazolidine, H-Asn-pyrrolidine, H-Asn-thiazolidine, H-Asp pyrrolidine, H-Asp-thiazolidine, H-Asp(NHOH)-pyrrolidine, H-Asp(NHOH)-thiazolidine, H-Glu-pyrrolidine, H-Glu-thiazolidine, H-Glu(NHOH)-pyrrolidine, H-Glu(NHOH) thiazolidine, H-His-pyrrolidine, H-His-thiazolidine, H-Pro-pyrrolidine, H-Pro thiazolidine, H-Ile-azididine, H-lle-pyrrolidine, H-L-allo-Ile-thiazolidine, H-Val pyrrolidine and H-Val-thiazolidine and pharmaceutically acceptable salts thereof. These compounds are described in WO 99/61431 and EP 1 304 327. Furthermore, the present invention provides for the use of effectors of QC in combination with substrate-like peptide compounds useful for competitive modulation of dipeptidyl peptidase IV catalysis. Preferred peptide compounds are 2-Amino octanoic acid-Pro-lie, Abu-Pro-Ile, Aib-Pro-Ile, Aze-Pro-Ile, Cha-Pro-Ile, lle-Hyp-lie, lle-Pro-alio-lle, lie-Pro-t-butyl-Gly, Ile-Pro-Val, Nle-Pro-Ile, Nva-Pro-Ile, Orn-Pro-Ile, Phe-Pro-Ile, Phg-Fro-lle, Pip-Pro-lIe, Ser(Bzl)-Pro-lle, Ser(P)-Pro-lle, Ser-Pro-Ile, t butyl-Gly-Pro-D-Val, t-butyl-Gly-Pro-Gly, t-butyl-Gly-Pro-lie, t-butyl-Gly-Pro-ile-amide, t-butyl-Gly-Pro-t-butyl-Gly, t-butyl-Gly-Pro-Val, Thr-Pro-Ile, Tic-Pro-Ile, Trp-Pro-lie, Tyr(P)-Pro-lie, Tyr-Pro-alo-lie, Val-Pro-allo-lie, Val-Pro-t-butyl-Gly, Val-Pro-Val and pharmaceutically acceptable salts thereof, wherein t-butyl-Gly is defined as
H
2 N COOH and Ser(Bzl) and Ser(P) are defined as benzyl-serine and phosphoryl-serine, respectively. Tyr(P) is defined as phosphoryl-tyrosine. These compounds are dislcosed in WO 03/002593. Further preferred DP IV-inhibitors, which can be used according to the present invention in combination with effectors of QC, are peptidylketones, e.g.
26 * 2-Methylcarbonyl-1-N-[(L)-Alanyl-(L)-Valinyl]-(2S)-pyrrolidine hydrobromide, 2 Methyl)carbonyl-1 -N-[(L)-Valinyl-(L)-Prolyl-(L)-Valinyl]-(2S)-pyrrolidine hydrobromicle, " 2-{(Acetyl-oxy-methyl)carbonyl)-1 -N-{(L)-Alanyl-(L)-Valinyl]-(2S)-pyrrolidine hydrobromicle, * 2-(Benzoyl-oxy-methyl)carbonyl}-1 -N-[{(L)-Alanyl}-(L)-Valinyl]-(2S)-pyrrolidine hydrobromide, * 2-{{(2,6-Dichlorbenzyl)thiomethylcarbonyl}-1 -N-{{(L)-Alanyl}-(L)-ValinylI-(2S) pyrrolidine, * 2-[Benzoy-loxy-methyl)carbonyl]-1 -N-[Glycyl-(L)-Valinyl]-(2S)-pyrrolidine hydrobromide, " 2-{([1,3)-Thiazolethiazol-2-yl)carbonyl)-1 -N-[{(L)-Alanyl)-(L)-Valinyl]-(2S) pyrrolidine trifluoracetate, " 2-[(Benzothiazolethiazol-2-yl)carbonyl]-1-N-[N-{(L)-Alanyl}-(L)-Valinyl]-(2S) pyrrolidin tri fluoracetate, " 2-{(-Benzothiazolethiazol-2-yl)carbonyl]-1 -N-[((L)-Alanyl)-Glycyl]-(2S) pyrrolidine trifluoracetate, " 2-[(Pyridin-2-yl)carbonyl]- 1 -N-[N-{(L)-Alanyl}-(L)-Valinyl]-(2S)-pyrrolidine trifluoracetate and other pharmaceutically acceptable salts thereof. These compounds are disclosed in WO 03/033524. Further, according to the present invention substituted aminoketones can be used in combination with effectors of QOC. Preferred substituted aminoketones are o 1-cyclopentyl-3-methyl-1-oxo-2-pentanaminium chloride, . 1-cyclopentyl-3-methyl-1 -oxo-2-butanaminium chloride, * 1 -cyclopeniyl-3,3-dimethyl- 1 -oxo-2-butanaminium chloride, * 1 -cyclohexyl-3,3-dimethyl-1 -oxo-2-butanaminium chloride, * 3-(cycloperntylcarbonyl)-1,2,3,4-tetrahydroisoquinolinium chloride, * N-(2-cyclopentyl-2-oxoethyl)cyclohexanaminium chloride and other pharmaceutically acceptable salts thereof.
27 Among the rare group of proli ne-specific proteases, DP IV was originally believed to be the only membrane-bound enzyme specific for proline as the penultimate residue at the amino-terminus of the polypeptide chain. However, other molecules, even those structurally non-homologous with the DP IV but bearing corresponding enzyme activity, have been identified. DP IV-like enzymes, which have been identified so far, include e.g. fibroblast activation protein a, dipeptidyl peptidase IV P, dipeptidyl aminopeptidase-like protein, N-acetylated a-linked acidic dipeptidase, quiescent cell proline dipeptidase, dipeptidyl peptidase 11, attractin and dipeptidyl peptidase IV related protein (DPI? 8), DPL1 (DPX, DP6), DPL2 and DPP 9 described in review articles by Sedo & Malik (Sedo and Malik 2001, Biochim Biophys Acta, 36506, 1-10) and Abbott and Gorrell (Abbott, C.A. and Gorrell, M.D. 2002 In: Langner & Ansorge (ed.), Ectopeptidases. Kluwer Academic/Plenum Publishers, New York, 171-195). Recently, the cloning and characterization of dipeptidyl peptidase 10 (DPP 10) was reported (0i, S.Y. et al., Biochemical Journal Immediate Publication. Published on 28 Mar 2003 as manuscript BJ20021914). Effectors, as that term is used herein, are defined as molecules that bind to enzymes and increase or decrease their activity in vitro and/or in vivo. Some enzymes have binding sites for small molecules that affect their catalytic activity; a stimulator molecule is called an activator. Enzymes may even have multiple sites for recognizing more than one activator or inhibitor. Enzymes can detect concentrations of a variety of molEcules and use that information to vary their own activities. Effectors can modulate enzymatic activity because enzymes can assume both active and inactive confirmations: activators are positive effectors, inhibitors are negative effectors. Effectors act not only at the active sites of enzymes, but also at regulatory sites, or allosteric sites, terms used to emphasize that the regulatory site is an element of the enzyme distinct from the catalytic site and to differentiate this form of regulation from competition between substrates and inhibitors at the catalytic site (Darnell, J., Lodish, H. and Baltimore, D. 1990, Molecular Cell Biology 2"d Edition, Scientific American Books, New York, page 63).
28 In the peptides of the present invention, each amino acid residue is represented by a one-letter or a three-letter designation, corresponding to the trivial name of the amino acid, in accordance with the following conventional list: Amino Acid One-Letter Symbol Three-Letter Symbol Alanine A Ala Arginine R Arg Asparagine N Asn Aspartic acid D Asp Cysteine C Cys Glutamine Q GIn Glutamic acid E Glu Glycine G Gly Histidine H His Isoleucine I Ile Leucine L Leu Lysine K Lys Methionine M Met Phenylalanine F Phe Proline P Pro Serine S Ser Threonine T Thr Tryptophan W Trp Tyrosine Y Tyr Valine V Val The term "QC" a:s used herein comprises glutaminyl cyclase (0C) and 0C-like enzymes. QC and 0C-ike enzymes have identical or similar enzymatic activity, further defined as QC activity. In this regard, QOC-like enzymes can fundamentally differ in their molecular structure from QC.
29 The term "QC activity" as used herein is defined as intramolecular cyclization of N terminal glutamine residues into pyroglutamic acid (pGlu*) or of N-terminal L homoglutamine or L-p-homoglutamine to a cyclic pyro-homoglutamine derivative under liberation of ammonia. See therefore schemes 1 and 2. Scheme 1: Cyclization of glutamine by OC peptide peptide NH HN H O
NH
3 NH
NH
2 QC 0 Scheme 2: Cyclization of L-homoglutamine by QC peptide pepide NH HN H O O
NH
3 NH O QC 0
NH
2 The term "EC" as used herein comprises the side activity of QC and OC-like enzymes as glutamate cyclase (EC), further defined as EC activity.
30 The term "EC activity" as used herein is defined as intramolecular cyclization of N terminal glutamate residues into pyroglutamic acid (pGlu*) by 0C. See therefore scheme 3. The term "metal-dependent enzyme" as used herein is defined as enzyme(s) that require a bound metal ion in order to fulfill their catalytic function and/or require a bound metal ion in order to form the catalytically active structure. Molecules that bind to enzymes and increase or decrease their activities are called "effectors". Effectors can modify enzymatic activity because enzymes can assume both active and inactive conformations: activators are positive effectors; inhibitors are negative effectors. Effectors bind at regulatory sites, or allosteric sites (from the Greek for "another shape"), a term used to emphasize that the regulatory site is an element of the enzyme distinct from the catalytic site and to differentiate this form of regulation from competition between substrates and inhibitors at the catalytic site. According to the individual embodiments of the present invention, either activators or inhibitors are preferred. Scheme 3: N-terminal cyclization of uncharged glutamyl peptides by OC (EC) peptide peptide NH NH H H H 0 H 2 0 0 0 0 (-5.0q*k7.0)
NH
2 NH 0- 0'40) QC/EC QC/EC 0 0 O OH H2N 0 Another aspect of the present invention is the identification of new physiological substrates of QC. These were identified by performing cyclization experiments with mammalian peptides as described in example 5. Prior, human QC and papaya 0C 31 were isolated as described in example 1. The applied methods are described in example 2, and the peptide synthesis employed is outlined in example 6. The results of the study are shown in Table 1. Table 1: New physiological substrates of glutaminyl cyclase (*, determined qualitatively by MALD1-TOF experiments) Substrate Human QC Papaya OC Km (pKM) kcal km Km (pM) ka, keadKu (s' ) (mM 1 s') (s')- (mM'' s'') [GIn']-Gastrin 31 ±1 54.1 ±0.6 1745.2 136.9 34 ±2 25.8 ±0.5 759 130 GIn]-Neurotensin 37 ±1 48.8 ±0.4 1318.9 ±24.8 40±3 35.7 ±0.9 893 ±44 [Gin']-FPP 87 t2 69.6 ±0.3 800.0 ±14.9 232 ±9 32.5 ±0.4 140 ±4 [GIn'].TRH 90±4 82.8 ±1.2 920.0 ±27.6 n.d. n.d. n.d. [GIn']-GnRH 53±3 69.2±1.1 1305.7±53.2 169±9 82.5±1.9 488.2±14.8 [GIn-glucagon(3-29) I [Gin]-substance P(5- * All analyses were performed in the optimal range of activity and stability of either human or plant 0C, as demonstrated in example 4. The amino acid sequences of physiological active peptides having an N-terminal glutamine residue and being therefore substrates for the 0C enzyme are listed in Table 2: Table 2: Amino acid sequences of physiological active peptides with an N terminal glutamine residue Peptide Amino acid sequence Function Gastrin 17 QGPWL EEEEEAYGWM DF Gastrin stimulates the (amide) stomach mucosa to produce Swiss-Prot: P01 350 and secrete hydrochloric acid and the pancreas to secrete its digestive enzymes. It also stimulates smooth muscle contraction and increases blood circulation and water secretion in the stomach and intestine.
32 Neurotensin QLYENKPRRP YIL Neurotensin plays an Swiss-Prot: P30990 endocrine or paracrine role in the regulation of fat metabolism. It causes contraction of smooth muscle. FPP QEP amide A tripeptide related to thyrotrophin releasing hormone (TRH), is found in seminal plasma. Recent evidence obtained in vitro and in vivo showed that FPP plays an important role in regulating sperm fertility. TRH QHP amide TRH functions as a regulator of the biosynthesis of TSH in Swiss-Prot: P20396 the anterior pituitary gland and as a neurotransmitter/ neuromodulator in the central and peripheral nervous systems. GnRH QHWSYGL RP(G) amide Stimulates the secretion of Swiss-Prot: P01 14E. gonadotropins; it stimulates the secretion of both luteinizing and follicle stimulating hormones. CCL16 (small QPKVPEW VNTPSTCCLK Shows chemotactic activity cytokine YYEKVLPRRL VVGYRKALNC for lymphocytes and inducible HLPAIIFVTK RNREVCTNPN monocytes but not A16) DDWVQEYIKD PNLPLLPTRN neutrophils. Also shows LSTVKIITAK NGQPOLLNSQ potent myelosuppressive activity, suppresses Swiss-Prot: proliferation of myeloid 015467 progenitor cells. Recombinant SCYA1 6 shows chemotactic activity for monocytes and THP-1 monocytes, but not for resting lymphocytes and neutrophils. Induces a calcium flux in THP-1 cells that were desensitized by prior expression to RANTES. CCL8 (small QPDSVSI PITCCFNVIN Chemotactic factor that 33 inducible cytokine RKIPIQRLES YTRITNIQCP attracts monocytes, KEAVIFKTKR GKEVCADPKE lymphocytes, basophils and A8) RWVRDSMKHL DQlFQNLKP eosinophils. May play a role in neoplasia and Swiss-Prot: P80075 inflammatory host responses. This protein can bind heparin. CCL2 (small QPDAINA PVTCCYNFTN Chemotactic factor that inducible cytokine RKISVQRLAS YRRITSSKCP attracts monocytes and A2) KEAVIFKTIV AKEICADPKQ basophils but not neutrophils Swiss-Prot: P13500 KWVQDSMDHL DKOTQTPKT or eosinophils. Augments monocyte anti-tumor activity. Has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis. Binds to CCR2 and CCR4. CCL18 (small QVGTNKELC CLVYTSWQlP Chemotactic factor that inducible cytokine QKFIVDYSET SPQCPKPGVI attracts lymphocytes but not Al 8) LLTKRGRQIC ADPNKKWVQK monocytes or granulocytes. YISDLKLNA May be involved in B cell Swiss-Prot: P 4 migration into B cell follicles in lymph nodes. Attracts naive T lymphocytes toward dendritic cells and activated macrophages in lymph nodes, has chemotactic activity for naive T cells, CD4+ and CD8+ T cells and thus may play a role in both humoral and cell-mediated immunity responses. Fractalkine QHHGVT KCNITCSKMT The soluble form is (neurotactin) SKIPVALLIH YQQNQASCGK chernotactic for T cells and RAIILETRQH RLFCADPKEQ monocytes, but not for Swiss-Prot: P7842:3 WVKDAMQHLD RQAAALTRNG neutrophils. The membrane GTFEKQIGEV KPRTTPAAGG bound form promotes MDESVVLEPE ATGESSSLEP adhesion of those leukocytes TPSSQEAQRA LGTSPELPTG to endothelial cells. May play 34 VTGSSGTRLP PTPKAQDGGP a role in regulating leukocyte VGTELFRVPP VSTAATWOSS adhesion and migration APHOPGPSLW AEAKTSEAPS processes at the TQDPSTQAST ASSPAPEENA endothelium. Binds to PSEGQRVWGQ GQSPRPENSL cx3crl. EREEMGPVPA HTDAFQDWGP GSMAHVSVVP VSSEGTPSRE PVASGSWTPK AEEPIHATMD PQRLGVLITP VPDAQAATRR QAVGLLAFLG LLFCLGVAMF TYQSLQGCPR KMAGEMAEGL RYIPRSCGSN SYVLVPV CCL7 (small QPVGINT STTCCYRFIN Chemotactic factor that inducible cytokine KKIPKQRLES YRRTTSSHCP attracts monocytes and A7) REAVIFKTKL DKEICADPTQ eosinophils, but not Swiss-Prot P80098 KWVQDFMKHL DKKTOTPKL neutrophils. Augments monocyte anti-tumor activity. Also induces the release of gelatinase B. This protein can bind heparin. Binds to CCR1, CCR2 and CCR3. Orexin A OPLPDCCROK TCSCRLYELL Neuropeptide that plays a (Hypocretin-1) HGAGNHAAGI LTL significant role in the regulation of food intake and Swiss-Prot 043612 sleep-wakefulness, possibly by coordinating the complex behavioral and physiologic responses of these complementary homeostatic functions. It plays also a broader role in the homeostatic regulation of energy metabolism, autonomic function, hormonal balance and the regulation of body fluids. Orexin-A binds to both OX1 R and OX2R with a high 17affinity. Substance P RPK PQQFFGLM Belongs to the tachykinins. Tachykinins are active peptides which excite neurons, evoke behavioral responses, are potent vasodilators and 35 secretagogues, and contract (directly or indirectly) many smooth muscles. In a fourth embodiment, the peptides [Gln')Gastrin (17 and 34 amino acids in length), [Gin']Neurotensin and (Gln']FPP were identified as new physiological substrates of QC. Gastrin, Neurotensin and FPP comprise a pGlu residue in their N-terminal position. This N-terminal pGlu residue was shown to be formed from N-terminal glutamine by 0C catalysis for all peptides. As a result, these peptides are activated in terms of their biological function upon conversion of the N-terminal glutamine residue to pGlu. Transepithelial transducing cells, particularly the gastrin (G) cell, co-ordinate gastric acid secretion with the arrival of food in the stomach. Recent work showed that multiple active products are generated from the gastrin precursor, and that there are multiple control points in gastrin biosynthesis. Biosynthetic precursors and intermediates (progastrin and Gly-gastrins) are putative growth factors; their products, the amidated gastrins, regulate epithelial cell proliferation, the differentiation ol acid-producing parietal cells and histamine-secreting enterochromaffin-like (ECL) cells, and the expression of genes associated with histamine synthesis and storage in ECL cells, as well as acutely stimulating acid secretion. Gastrin also stimulates the production of members of the epidermal growth factor (EGF) family, which in turn inhibit parietal cell function but stimulate the growth of surface epithelial cells. Plasma gastrin concentrations are elevated in subjects with Helicobacter pylorf, who are known to have increased risk of duodenal ulcer disease and gastric cancer (Dockray, G.J. 1999 J Physiol 15 315-324). The peptide hormone gastrin, released from antral G cells, is known to stimulate the synthesis and release of histamine from ECL cells in the oxyntic mucosa via CCK-2 receptors. The mobilized histamine induces acid secretion by binding to the H(2) receptors located on parietal cells. Recent studies suggest that gastrin, in both its fully amidated and less processed forms (progastrin and glycine-extended gastrin), is 36 also a growth factor for the gastrointestinal tract. It has been established that the major trophic effect of amidated gastrin is for the oxyntic mucosa of stomach, where it causes increased proliferation of gastric stem cells and ECL cells, resulting in increased parietal and ECL cell mass. On the other hand, the major trophic target of the less processed gastrin (e.g. glycine-extended gastrin) appears to be the colonic mucosa (Koh, T.J. and Chen, D. 2000 Regul Pept 9337-44). In a fifth embodiment, the present invention provides the use of activity increasing effectors of QC for the stimulation of gastrointestinal tract cell proliferation, especially gastric mucosal cell proliferation, epithelial cell proliferation, the differentiation of acid-producing parietal cells and histamine-secreting enterochromaffin-like (ECL) cells, and the expression of genes associated with histamine synthesis and storage in ECL cells, as well as for the stimulation of acute acid secretion in mammals by maintaining or increasing the concentration of active {pGlul)-Gastrin. In a sixth embodiment, the present invention provides the use of activity decreasing effectors of 0C for the treatment of duodenal ulcer disease and gastric cancer with or w/o Heliobacter pylori in mammals by decreasing the conversion rate of inactive {Gln']Gastrin to active [pGlu']Gastrin. Neurotensin (NT) is a neuropeptide implicated in the pathophysiology of schizophrenia that specifically modulates neurotransmitter systems previously demonstrated to be misregulated in this disorder. Clinical studies in which cerebrospinal fluid (CSF) NT concentrations have been measured revealed a subset of schizophrenic patients with decreased CSF NT concentrations that are restored by effective antipsychotic drug treatment. Considerable evidence also exists concordant with the involvement of NT systems in the mechanism of action of antipsychotic drugs. The behavioral and biochemical effects of centrally administered NT remarkably resemble those of systemically administered antipsychotic drugs, and antipsychotic drugs increase NT neurotransmission. This concatenation of findings led to the hypothesis that NT functions as an endogenous antipsychotic. Moreover, typical and atypical antipsychotic drugs differentially alter NT neurotransmission in 37 nigrostriatal and nesolimbic dopamine terminal regions, and these effects are predictive of side effect liability and efficacy, respectively (Binder, E. B. et al. 2001 Biol Psychiatry 50 856-872). In a seventh embodiment, the present invention provides the use of activity increasing effectors of OC for the preparation of antipsychotic drugs and/or for the treatment of schizophrenia in mammals. The effectors of QC either maintain or increase the concentration of active [pGlu']neurotensin. Fertilization promoting peptide (FPP), a tripeptide related to thyrotrophin releasing hormone (TRH), is found in seminal plasma. Recent evidence obtained in vitro and in vivo showed that FPP plays an important role in regulating sperm fertility. Specifically, FPP initially stimulates nonfertilizing (uncapacitated) spermatozoa to "switch on" and become fertile more quickly, but then arrests capacitation so that spermatozoa do not undergo spontaneous acrosome loss and therefore do not lose fertilizing potential. These responses are mimicked, and indeed augmented, by adenosine, known to regulate the adenylyl cyclase (AC)/cAMP signal transduction pathway. Both FPP and adenosine have been shown to stimulate cAMP production in uncapacitated cells but inhibit it in capacitated cells, with FPP receptors somehow interacting with adenosine receptors and G proteins to achieve regulation of AC. These events affect the tyrosine phosphorylation state of various proteins, some being important in the initial "switching on," others possibly being involved in the acrosome reaction itself. Calcitonin and angiotensin 11, also found in seminal plasma, have similar effects in vitro on uncapacitated spermatozoa and can augment responses to FPP. These molecules have similar effects in vivo, affecting fertility by stimulating and then maintaining fertilizing potential. Either reductions in the availability of FFP, adenosine, calcitonin, and angiotensin I or defects in their receptors contribute to male infertility (Fraser, L.R. and Adeoya-Osiguwa, S. A. 2001 Vitam Horm 63, 1-28). In an eight embodiment, the present invention provides the use of activity lowering effectors of OC for the preparation of fertilization prohibitive drugs and/or to reduce 38 the fertility in mammals. The activity lowering effectors of QC decrease the concentration of active [pGlu']FPP, leading to a prevention of sperm capacitation and deactivation of sperm cells. In contrast it could be shown that activity increasing effectors of OC are able to stimulate fertility in males and to treat infertility. In a ninth embodiment, further physiological substrates of QC were identified within the present invention. These are [Gln']CCL2, [Gln']CCL7, [Gln 1 ]CCL8, [GIn']CCL16, [Gln')CCL18 and [GlIn')fractalkine. For details see Table 2. These polypeptides play an important role in pathophysiological conditions, such as suppression of proliferation of myeloid progenitor cells, neoplasia, inflammatory host responses, cancer, psoriasis, rheumatoid arthritis, atherosclerosis, humoral and cell-mediated immunity responses, leukocyte adhesion and migration processes at the endothelium. Several cytotoxic T lymphocyte peptide-based vaccines against hepatitis B, human immunodeficiency virus and melanoma were recently studied in clinical trials. One interesting melanoma vaccine candidate alone or in combination with other tumor antigens, is the decapeptide ELA. This peptide is a Melan-A/MART-1 antigen immunodominant peptide analog, with an N-terminal glutamic acid. It has been reported that the amino group and gamma-carboxylic group of glutamic acids, as well as the amino group and gamma-carboxamide group of glutamines, condense easily to form pyroglutamic derivatives. To overcome this stability problem, several peptides of pharmaceutical interest have been developed with a pyroglutamic acid instead of N-terminal glutamine or glutamic acid, without loss of pharmacological properties. Unfortunately compared with ELA, the pyroglutamic acid derivative (PyrELA) and also the N-terminal acetyl-capped derivative (AcELA) failed to elicit cytotoxic T lymphocyte (CTL) activity. Despite the apparent minor modifications introduced in PyrELA and AcELA, these two derivatives probably have lower affinity than ELA for the specific class I major histocompatibility complex. Consequently, in order to conserve full activity of ELA, the formation of PyrELA must be avoided (Beck A. et al. 2001, J Pept Res 57(6):528-38.). Recently, it was found that also the enzyme 39 glutaminyl cyclase (QC) is overexpressed in melanomas (Ross D. T et al., 2000, Nat Genet 24:227-35.). In a tenth embodiment, the present invention provides the use of effectors of QOC for the preparation of a medicament for the treatment of pathophysiological conditions, such as suppression of proliferation of myeloid progenitor cells, neoplasia, inflammatory host responses, cancer, malign metastasis, melanoma, psoriasis, rheumatoid arthritis, atherosclerosis, impaired humoral and cell-mediated immunity responses, leukocyte adhesion and migration processes at the endothelium. In an eleventh embodiment, {Gln')orexin A was identified as a physiological substrate of OC within the present invention. Orexin A is a neuropeptide that plays a significant role in the regulation of food intake and sleep-wakefulness, possibly by coordinating the complex behavioral and physiologic responses of these complementary homeostatic functions. It plays also a role in the homeostatic regulation of energy metabolism, autonomic function, hormonal balance and the regulation of body fluids. In a twelfth embodiment, the present invention provides the use of effectors of QC for the preparation of a medicament for the treatment of impaired food intake and sleep wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance and impaired regulation of body fluids. Polyglutamine expansions in several proteins lead to neurodegenerative disorders, such as Parkinson disease and Kennedy's disease. The mechanism therefore remains largely unknown. The biochemical properties of polyglutamine repeats suggest one possible explanation: endolytic cleavage at a glutaminyl-glutaminyl bond followed by pyroglutamate formation may contribute to the pathogenesis through augmenting the catabolic stability, hydrophobicity, amyloidogenicity, and neurotoxicity of the polyglutaminyl proteins (Saido, T; Med Hypotheses (2000) Mar;54(3):427-9). In a thirteenth embodiment, the present invention provides 40 therefore the use of effectors of OC for the preparation of a medicament for the treatment of Parkinson disease and Huntington's disease. In a fourteenth embodiment, the present invention provides a general way to reduce or inhibit the enzymatic activity of 0C. Examples of inhibitory compounds are also provided. Inhibition of a mammalian QC was only detected initially for 1,10-phenanthroline and reduced 6-methylpterin (Busby, W. H. J. et al. 1987 J Biol Chem 262, 8532-8536). EDTA did not inhibit 0C, thus it was concluded that QC is not a metal-dependent enzyme (Busby, W. H. J. et al. 1987 J Biol Chem 262, 8532-8536, Bateman, R.C.J. et al. 2001 Biochemistry 40, 11246-11250, Booth, R.E. et al. 2004 BMC Biology 2). In the present invention, however, it is shown that human 0C and other animal OCs are metal-dependent enzymes, as revealed by the inhibition characteristics of QC by 1,10-phenanthroline, dipicolinic acid, 8-hydroxy-quinoline and other chelators (Figures 18,19) and by the reactivation of 0C by transition metal ions (Figure 20). Finally, the metal dependence is outlined by a sequence comparison to other metal dependent enzymes, showing a conservation of the chelating amino acid residues also in human QC (Figure 21). The interaction of compounds with the active-site bound metal ion represents a general way to reduce or inhibit 0C activity. In the present invention it is shown that imidazole derivatives are potent inhibitors of QC. Using the continuous assay (for details see example 2), many imidazole derivatives were analyzed concerning their ability to inhibit the human QOC as a member of the highly conserved mammalian QCs. Thus, the present invention provides imidazole derivatives and histidine and its derivatives as activity reducing effectors of QC and their characteristics in terms of inhibition type and potency. Structures and Kr-values are shown in tables 3 and 4. The results are described in detail in example 7. Table 3: Inhibitory constants of Imidazole derivatives In the human OC catalyzed reaction. Determinations were performed at 30 "C In 0.05 M 41 Tris-HCI pH 8.0, containing 5 mM EDTA. Compound Krvalue (mM) Structure core structures imidazole 0.103 ±0,004 benzimidazole 0.138 ±0.005 N-1 derivatives 1-benzylimidazole 0.0071 ±0.0003 1 -methylimidazole 0.030 ±0.001 1-vinylimidazole 0.049 ±0.002 oxalic acid diimidazolidide 0.078 ±0.002 N-acetylimidazole 0.107 ±0.003 N-(trimethylsilyl)-imidazole 0.167 ±0.007 N-benzoylimidazole 0.174 ±0.007 1-(2-oxo-2-phenyl-ethyl)- 0.184 ±0.005 imidazole 1-(3-aminopropyl)-i midazole 0.41 ±0.01 1 -phenylimidazole no inhibition 1,1'-sulfonyldiimidazole no inhibition C-4(5) derivatives N-omega-acetylhistamine 0.017 ±0.001 L-histidinamide 0.56 ±0.04 H-His-Trp-OH 0.60 ±0.03 L-histidinol 1.53 ±0.12 L-histidine 4.4 ±0.2 4-imidazole-carboxaldehyde 7.6 ±0.7 imidazole-4-carbonic acid 14.5 ±0.6 methylester L-histamine 0.85 ±0.04 C-4,5 derivatives 5-hydroxymethyl-4-methyl- 0.129 ±0.005 imidazole 4-amino-imidazole-5-carbonic 15.5 ±0.5 acid amide 4,5-diphenyl-imidazole no inhibition 4,5-dicyanoimidazole no inhibition C-2 derivatives 2-methyl-benzylimidazole 0.165 ±0.004 2-ethyl-4-methyl-irnidazole 0.58 ±0.04 2-aminobenzimidazole 1.8±0.1 2-chloro-1 H-benzimidazole no inhibition 42 Others 3-(l H-imidazol- 1 -yl)-l1 -(3- 0.0025 ±0.0001 methylbenzo~b]thiophefle-2 ylpropan-1 -one 44[(1-methyl-i H-irnidazol-5- 0,0067± 0.0003 yI)methyl]-3 p ropyldihydrofu ran-2-(3H) 6thoxy~benzoic acid 0.0034 ±0,0001 3-[3-(l H-imidazol- I -yt)propyl] 2-thioxoimidazolidifl-4-ofle 0.00041 ±0.00001 5-nhtlro-2-[2-(t{3-(1 H-irnidazol 1 -yl-)propyl)amino] 0.0066 ±0,0004 carbonyl)phenyl]furamfide N-(4-chlorophenyl)-N'-[2-(1
H
imidazoi-1 -yl)ethyl]thiourea 0.00165 ±0.00007 \ N0 0,0322 ±0,0007 1-2,3- n.d. nic 90 43 Imidazo<1.5a>pyridine 0.0356 ±0.0005 NN Methyl (2S)-2-{[(2S)-2-amino- 0.164 ±0.004 5-(1 H-imidazol-1 -ylamino)-5- H2N O oxopentanoylarnino)-3- N methylbutanoate 0 N' N H Table 4: OC inhibition by L-histamine and Its two biological metabolites (also known as tele-methylhistamine). Compound Ki value (mM) Structure NH L-histamine 0.85 ±0.04 0.120 ±0.004 3-methyl-4-(f#-aminoethyl)- 0 . irnidazole 1 -methyl-4-(#-aminoethyl)- n.i.N irnidazole Surprisingly, during characterization of the enzymatic activity it was discovered that besides an N-terminal glutaminyl residue, N-terminal 0-homo-glutaminyl residues also fulfill properties as substrates of QCs from plants and mammals. The N-terminal p-homo-glutaminyl residue was converted into a five-membered lactam ring by 44 catalysis of human and papaya QC, respectively. The results are described in example 5. The applied method is illustrated in example 2 and the peptide synthesis was performed as described in example 6. Another preferred embodiment of the present invention comprises screening methods for effectors of QC. A preferred screening method for identifying activity modifying effectors of OC from a group of compounds comprises the steps of: a) Contacting said compounds with QC under conditions which would permit binding therebetween; b) Adding a substrate of QC; c) Monitoring the conversion of the substrate or optionally measuring the residual QC activity; and d) Calculating changes in the substrate conversion and/or enzyme activity of QC to identify an activity modifying effector. Another preferred screening method relates to a method for the identification and selection of effectors which interact directly or indirectly with the active-site bound metal ion of 0C and comprises the following steps: a) Contacting said compounds with QC under conditions which would permit binding therebetween; b) Adding a substrate of OC which is subject to conversion by QC; c) Monitoring the conversion of the substrate or optionally measuring the residual 0C activity; and d) Calculating changes in the substrate conversion and/or enzyme activity of QC wherein changes may be used to identify an activity modifying effector of QC. Preferred for the Use in the above described screening methods are mammalian QOC or Papaya 0C. Especially preferred is mammalian 0C, since the effectors identified 45 by these screening methods shall be used for the treatment of diseases in mammals, especially in humans. The agents selected by the above described screening methods can work by decreasing the conversion of at least one substrate of QC (negative effectors, inhibitors), or by increasing the conversion of at least one substrate of QOC (positive effectors, activators). The compounds of the present invention can be converted into acid addition salts, especially pharmaceutically acceptable acid addition salts. The salts of the compounds of the invention may be in the form of inorganic or organic salts. The compounds of the present invention can be converted into and used as acid addition salts, especially pharmaceutically acceptable acid addition salts. The pharmaceutically acceptable salt generally takes a form in which a basic side chain is protonated with an inorganic or organic acid. Representative organic or inorganic acids include hydrochloric, hydrobromic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toulenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic acid. All pharmaceutically acceptable acid addition salt forms of the compounds of the present invention are intended to be embraced by the scope of this invention. In view of the close relationship between the free compounds and the compounds in the form of their salts, whenever a compound is referred to in this context, a corresponding salt is also intended, provided such is possible or appropriate under the circumstances.
46 Where the compounds according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, some of the crystalline forms of the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e. hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention. The compounds, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization. In a further embodiment, the present invention provides a method of preventing or treating a condition mediated by modulation of the OC enzyme activity in a subject in neEd thereof which comprises administering any of the compounds of the present invention or pharmaceutical compositions thereof in a quantity and dosing regimen therapeutically effective to treat the condition. Additionally, the present invention includes the use of the compounds of this invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for the preparation of a medicament for the prevention or treatment of a condition mediated by modulation of the QC activity in a subject. The compound may be administered to a patient by any conventional route of administration, including, but not limited to, intravenous, oral, subcutaneous, intramuscular, intradermal, parenteral and combinations thereof. In a further preferred form of implementation, the invention relates to pharmaceutical compositions, that is to say, medicaments, that contain at least one compound of the invention or salts thereof, optionally in combination with one or more pharmaceutically acceptable carriers and/or solvents. The pharmaceutical compositions may, for example, be in the form of parenteral or 47 enteral formulations and contain appropriate carriers, or they may be in the form of oral formulations that may contain appropriate carriers suitable for oral administration. Preferably, they are in the form of oral formulations. The effectors of OC activity administered according to the invention may be employed in pharmaceutically administrable formulations or formulation complexes as inhibitors or in combination with inhibitors, substrates, pseudosubstrates, inhibitors of OC expression, binding proteins or antibodies of those enzyme proteins that reduce the QC protein concentration in mammals. The compounds of the invention make it possible to adjust treatment individually to patients and diseases, it being possible, in particular, to avoid individual intolerances, allergies and side-effects. The compounds also exhibit differing degrees of activity as a function of time. The doctor providing treatment is thereby given the opportunity to respond differently to the individual situation of patients: he is able to adjust precisely, on the one hand, the speed of the onset of action and, on the other hand, the duration of action. and especially the intensity of action. A preferred treatment method according to the invention represents a new approach for the prevention or treatment of a condition mediated by modulation of the 0C enzyme activity in mammals. It is advantageously simple, susceptible of commercial application and suitable for use, especially in the treatment of diseases that are based on unbalanced concentration of physiological active QC substrates, e.g. listed in Tables 1 and 2, in mammals and especially in human medicine. The compounds may be advantageously administered, for example, in the form of pharmaceutical preparations that contain the active ingredient in combination with customary additives like diluents, excipients and/or carriers known from the prior art. For example, they can be administered parenterally (for example i.v. in physiological saline solution) or enterally (for example orally, formulated with customary carriers). Depending upon their endogenous stability and their bioavailability, one or more 48 doses of the compounds can be given per day in order to achieve the desired normalisation of the blood glucose values. For example, such a dosage range in humans may be in the range of from about 0.01 mg to 250.0 mg per day, preferably in the range of from about 0.01 to 100 mg of compound per kilogram of body weight. By administering effectors of QC activity to a mammal it could be possible to prevent or alleviate or treat conditions selected from Alzheimer's disease, Down Syndrome, ulcer disease and gastric cancer with or w/o Heliobacter pylori infections, pathogenic psychotic conditions, schizophrenia, infertility, neoplasia, inflammatory host responses, cancer, psoriasis, rheumatoid arthritis, atherosclerosis, impaired humoral and cell-mediated immune responses, leukocyte adhesion and migration processes in the endothelium, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance and impaired regulation of body fluids. Further, by administering effectors of OC activity to a mammal it could be possible to stimulate gastrointestinal tract cell proliferation, preferably proliferation of gastric mucosal cells, epithelial cells, acute acid secretion and the differentiation of acid producing parietal cells and histamine-secreting enterochromaffin-like cells. in addition, administration of QC inhibitors to mammals may lead to a loss of sperm cell function thus suppressing male fertility. Thus, the present invention provides a method for the regulation and control of male fertility and the use of activity lowering effectors of OC for the preparation of contraceptive medicaments for males. Furthermore, by administering effectors of QC activity to a mammal it may be possible to suppress the proliferation of myeloid progenitor cells. The compounds used according to the invention can accordingly be converted in a manner known per se into conventional formulations, such as, for example, tablets, capsules, drag6es, pills, suppositories, granules, aerosols, syrups, liquid, solid and cream-like emulsions and suspensions and solutions, using inert, non-toxic, 49 pharmaceutically suitable carriers and additives or solvents. In each of those formulations, the therapeutically effective compounds are preferably present in a concentration of approximately from 0.1 to 80 % by weight, more preferably from 1 to 50 % by weight, of the total mixture, that is to say, in amounts sufficient for the mentioned dosage latitude to be obtained. The substances can be used as medicaments in the form of drag6es, capsules, bitable capsules, tablets, drops, syrups or also as suppositories or as nasal sprays. The formulations may be advantageously prepared, for example, by extending the active ingredient with solvents and/or carriers, optionally with the use of emulsifiers and/or dispersants, it being possible, for example, in the case where water is used as diluent, for organic solvents to be optionally used as auxiliary solvents. Examples of excipients useful in connection with the present invention include: water, non-toxic organic solvents, such as paraffins (for example natural oil fractions), vegetable oils (for example rapeseed oil, groundnut oil, sesame oil), alcohols (for example ethyl alcohol, glycerol), glycols (for example propylene glycol, polyethylene glycol); solid carriers, such as, for example, natural powdered minerals (for example highly disperse silica, silicates), sugars (for example raw sugar, lactose and dextrose); emulsifiers, such as non-ionic and anionic emulsifiers (for example polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, alkylsulphonates and arylsulphonates), dispersants (for example lignin, sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (for example magnesium stearate, talcum, stearic acid and sodium lauryl sulphate) and optionally flavourings. Administration may be carried out in the usual manner, preferably enterally or parenterally, especially orally. In the case of enteral administration, tablets may contain in addition to the mentioned carriers further additives such as sodium citrate, calcium carbonate and calcium phosphate, together with various additives, such as starch, preferably potato starch, gelatin and the like. Furthermore, lubricants, such 50 as magnesium stearate, sodium lauryl sulphate and talcum, can be used concomitantly for tabletting. In the case of aqueous suspensions and/or elixirs intended for oral administration, various taste correctives or colourings can be added to the active ingredients in addition to the above-mentioned excipients. In the case of parenteral administration, solutions of the active ingredients using suitable liquid carriers can be employed. In general, it has been found advantageous to administer, in the case of intravenous administration, amounts of approximately from 0.01 to 2.0 mg/kg, preferably approximately from 0.01 to 1.0 mg/kg, of body weight per day to cbtain effective results and, in the case of enteral administration, the dosage is approximately from 0.01 to 2 mg/kg, preferably approximately from 0.01 to 1 mg/kg, of body weight per day. It may nevertheless be necessary in some cases to deviate from the stated amounts, depending upon the body weight of the experimental animal or the patient or upon the type of administration route, but also on the basis of the species of animal and its individual response to the medicament or the interval at which administration is carried out. Accordingly, it may be sufficient in some cases to use less than the above-mentioned minimum amount, while, in other cases, the mentioned upper limit will have to be exceeded. In cases where relatively large amounts are being administered, it may be advisable to divide those amounts into several single doses over the day. For administration in human medicine, the same dosage latitude is provided. The above remarks apply analogously in that case. Examples of pharmaceutical formulations 1. Capsules containing 100 mg of a compound of the invention per capsule: For approximately 10,000 capsules a solution of the following composition is prepared: 51 compound of the invention 1.0 kg glycerol 0.5 kg polyethylene glycol 3.0 kg water 0.5 ka 5.0 kg The solution is introduced into soft gelatin capsules in a manner known per Se. The capsules are suitable for chewing or swallowing. 2. Tablets or coated tables or dragees containing 100 mg of a compound of the invention: The following amounts refer to the preparation of 100,000 tablets: compound of the invention, finely ground 10.0 kg glucose 4.35 kg lactose 4.35 kg starch 4.50 kg cellulose, finely ground 4.50 kg The above constituents are mixed and then provided with a solution prepared from polyvinylpyrrolidonei 2.0 kg polysorbate 0.1 kg and water approx. 5.0 kg and granulated in a manner known per se by grating the moist mass and, after the addition of 0.2 kg of magnesium stearate, drying it. The finished tablet mixture of 30.0 kg is processed to form convex tablets weighing 300 mg. Ideally, the tablets can be coated or sugar-coated in a manner known per se.
52 The pharmaceutical compositions defined throughout the specification advantageously contain a combination of at least one effector of OC activity and at least one DP IV inhibitor. Such pharmaceutical compositions are especially useful for the treatment of Alzheimer's Disease and Down Syndrome. Example 1: Preparation of Human and Papaya OC Host strains and media Pichia pastoris strain X33 (AOX1, AOX2), used for the expression of human QC was grown, transformed and analyzed according to the manufacturer's instructions (Invitrogen). The media required for P. pastoris, i.e. buffered glycerol (BMGY) complex or methanol (BMMY) complex medium, and the fermentation basal salts medium were prepared according to the manufacturer's recommendations. Molecular cloning of plasmid vectors encoding the human 00 All cloning procedures were done applying standard molecular biology techniques. For expression in yeast, the vector pPICZaB (Invitrogen) was used. The pQE-31 vector (Qiagen) was used to express the human OC in E. coli. The cDNA of the mature QC starting with codon 38 was fused in frame with the plasmid encoded 6xhistidine tag. After amplification utilizing the primers pQCyc-1 and pQCyc-2 (Table 1) and subcloning, the fragment was inserted into the expression vector employing the restriction sites of Sphl and HindIll. Transformation of P. astoris and mini-scale expression Plasmid DNA was amplified in E. coi JM109 and purified according to the recommendations of the manufacturer (Qiagen). In the expression plasmid used, pPICZcB, three restriction sites are provided for linearization. Since Sac and BstXl cut within the QC: cDNA, Pmel was chosen for linearization. 20-30 pg plasmid DNA 53 was linearized with Pmel, precipitated by ethanol, and dissolved in sterile, deionized water. 10 pg of the DNA was then applied for transformation of competent P. pastors cells by electroporation according to the manufacturer's instructions (BioRad). Selection was done on plates containing 150 pg/ml Zeocin. One transformation using the linearized plasmid yielded several hundred transformants. In order to test the recombinant yeast clones for OC expression, recombinants were grown for 24 h in 10 ml conical tubes containing 2 ml BMGY. Afterwards, the yeast was centrifuged and resuspended in 2 ml BMMY containing 0.5 % methanol. This concentration was maintained by addition of methanol every 24 h up to 72 h. Subsequently, QC activity in the supernatant was determined. The presence of the fusion protein was confirmed by westem blot analysis using an antibody directed against the 6xhistidine tag (Qiagen). Clones that displayed the highest QC activity were chosen for further experiments and fermentation. Large-scale expression in a fermenter Expression of the QC was performed in a 5 I reactor (Biostat B, B. Braun biotech), essentially as described in the "Pichia fermentation process guidelines" (Invitrogen). Briefly, the cells were grown in the fermentation basal salts medium supplemented with trace salts, and with glycerol as the sole carbon source (pH 5.5). During an initial batch phase for about 24 h and a subsequent fed-batch phase for about 5 h, cell mass was accumulated. Once a cell wet weight of 200 g/l was achieved, induction of QC expression was performed using methanol applying a three-step feeding profile for an entire fermentation time of approximately 60 h. Subsequently, cells were removed from the QC-containing supernatant by centrifugation at 6000xg, 4 *C for 15 min. The pH was; adjusted to 6.8 by addition of NaOH, and the resultant turbid solution was centrifuged again at 37000xg, 4 *C for 40 min. In cases of continued turbidity, an additional filtration step was applied using a cellulose membrane (pore width 0.45 pm).
54 Purification of 6xhistidine taqqed 0C expressed in P. pastoris The His-tagged Q was first purified by immobilized metal affinity chromatography (IMAC). In a typical purification, 1000 ml of culture supernatant were applied to a Ni 2 ,-loaded Chelating Sepharose FF column (1.6 x 20 cm, Pharmacia), that was equilibrated with 50 mM phosphate buffer, pH 6.8, containing 750 mM NaCl, at a flow rate of 5 ml/min. After washing with 10 column volumes of equilibration buffer and 5 column volumes of equilibration buffer containing 5 mM histidine, the bound protein was eluted by a shift to 50 mM phosphate buffer, pH 6.8, containing 150 mM NaCl and 100 mM histidine. The resulting eluate was dialyzed against 20 mM Bis-Tris/HCI, pH 6.8, at 4 *C overnight. Subsequently, the QC was further purified by anion exchange chromatography on a Mono Q6 column (BioRad), equilibrated with dialysis buffer. The 0C-containing fraction was loaded onto the column using a flow rate of 4 ml/min. The column was then washed with equilibration buffer containing 100 mM NaCl. The elution was performed by two gradients resulting in equilibration buffer containing 240 mM and 360 mM NaCl in 30 or 5 column volumes, respectively. Fractions of 6 ml were collected and the purity was analyzed by SDS-PAGE. Fractions containing homogenous QC were pooled and concentrated by ultrafiltration. For long-term storage (-20 0C), glycerol was added to a final concentration of 50 %. Protein was quantified according to the methods of Bradford or Gill and von Hippel (Bradford, M. M. 1976 Anal Biochem 72, 248-254; Gill, S.C. and von Hippel, P.H. 1989 Anal Biochem 182, 319-326.). Expression and purification of 0C in E. coli The construct encoding the QC was transformed into M15 cells (Qiagen) and grown on selective LB agar plates at 37 *C. Protein expression was carried out in LB medium containing 1 % glucose and 1 % ethanol at room temperature. When the culture reached an ODeoo of approximately 0.8, expression was induced with 0.1 mM IPTG overnight. After one cycle of freezing and thawing, cells were lysed at 4 *C by addition of 2.5 mg'mi lysozyme in 50 mM phosphate buffer, pH 8.0, containing 300 mM NaCl and 2 mM histidine for approximately 30 min. The solution was clarified by centrifugation at 37000xg, 4 *C for 30 min, followed by a filtration applying a glass fruit (DNA separation) and two additional filtration steps applying cellulose filters for crude 55 and fine precipitates. The supernatant (approx. 500 ml) was applied onto a Ni2 affinity column (1.6 x 20 cm) at a flow rate of 1 mV min. Elution of QC was carried out with 50 mM phosphate buffer containing 150 mM NaCl and 100 mM histidine. The OC-containing fraction was concentrated by ultrafiltration. Purification of OC from napava latex QC from papaya latex was prepared using the BioCAD 700E (Perseptive Biosystems, Wiesbaden, Germany) with a modified version of a previously reported method (Zerhouni, S. et al. 1989 Biochim Biophys Acta 138, 275-290). 50 g latex was dissolved in water and centrifugated as described therein. Inactivation of proteases was performed with S-methyl methanethiosulfonate, and the resultant crude extract was dialyzed. After dialysis, the entire supernatant was loaded onto a (21X2.5 cm i.d.) SP Sepharose Fast Flow column, equilibrated with 100 mM sodium acetate buffer, pH 5.0 (flow rate 3 mVmin). Elution was performed in three steps by increasing sodium acetate buffer concentration at a flow rate of 2 mVmin. The first step was a linear gradient from 0.1 to 0.5 M acetate buffer in 0.5 column volumes. The second step was a linear increase in buffer concentration from 0.5 to 0.68 M in four column volumes. During the last elution step, one column volume of 0.85 M buffer was applied. Fractions (6 ml) containing the highest enzymatic activity were pooled. Concentration and buffer changes to 0.02 M Tris/HCI, pH 8.0 were performed via ultrafiltration (Amicon; molecular mass cut-off of the membrane 10 kDa). Ammonium sulfate was added to the concentrated papaya enzyme, obtained from the ion exchange chromatography step to a final concentration of 2 M. This solution was applied onto a (21X 2.5 cm i.d.) Butyl Sepharose 4 Fast Flow column (flow rate 1.3 mlmin), equilibrated with 2 M ammonium sulfate, 0.02 M Tris/HCI, pH 8.0. Elution was performed in three steps with decreasing concentrations of ammonium sulfate. During the first stop a linear gradient from 2 to 0.6 M ammonium sulfate, 0.02 M Tris/HCI, pH 8.0 was applied for 0.5 column volumes at a flow rate of 1.3 m/min. The second step was a linear gradient from 0.6 to 0 M ammonium sulfate, 0.02 M Tris/HCI, pH 8.0, in 5 column volumes at a flow rate of 1.5 mI/min. The last elution 56 step was carried out by applying 0.02 M Tris/HCI at pH 8.0 for 2 column volumes at a flow rate of 1.5 ml/min. All fractions containing 0C activity were pooled and concentrated by ultrafiltration. The resultant homogenous 0C was stored at -700C. Final protein concentrations were determined using the method of Bradford, compared to a standard curve obtained with bovine serum albumin. Example 2: Assays for glutaminyl cyclase activity Fluorometric assays All measurements were performed with a BioAssay Reader HTS-7000Plus for microplates (Perkin Elmer) at 30 *C. QC activity was evaluated fluorometrically using H-Gln-pNA. The samples consisted of 0.2 mM fluorogenic substrate, 0.25 U pyroglutamyl aminopeptidase (Unizyme, Hersholm, Denmark) in 0.2 M Tris/HCI, pH 8.0 containing 20 rnM EDTA and an appropriately diluted aliquot of QC in a final volume of 250 pl. Excitation/emission wavelengths were 320/410 nm. The assay reactions were initiated by addition of glutaminyl cyclase. 0C activity was determined from a standard curve of #-naphthylamine under assay conditions. One unit is defined as the amount of 0C catalyzing the formation of 1 pmol pGlu-#NA from H Gin-pNA per minute under the described conditions. In a second fluorometric assay, 0C was activity was determined using H-GIn-AMC as substrate. Reactions were carried out at 300C utilizing the NOVOStar reader for microplates (BMG labtechnologies). The samples consisted of varying concentrations of the fluorogenic substrate, 0.1 U pyroglutamyl aminopeptidase (Qiagen) in 0.05 M Tris/HCI, pH 8.0 containing 5 mM EDTA and an appropriately diluted aliquot of 0C in a final volume of 250 pl. Excitation/emission wavelengths were 380/460 nm. The assay reactions were initiated by addition of glutaminyl cyclase. QC activity was determined from a standard curve of 7-amino-4-methylcoumarin under assay conditions. The kinetic data were evaluated using GraFit sofware.
57 Spectrophotometric assay of OC This novel assay was used to determine the kinetic parameters for most of the QC substrates. OC activity was analyzed spectrophotometrically using a continuous method, that was derived by adapting a previous discontinuous assay (Bateman, R. C. J. 1989 J Neurosci Methods 30, 23-28) utilizing glutamate dehydrogenase as auxiliary enzyme. Samples consisted of the respective QC substrate, 0.3 mM NADH, 14 mM a-Ketoglutaric acid and 30 U/mi glutamate dehydrogenase in a final volume of 250 p. Reactions were started by addition of QC and persued by monitoring of the decrease in absotbance at 340 nm for 8-15 min. Typical time courses of product formation are presented in Figure 1. The initial velocities were evaluated and the enzymatic activity was determined from a standard curve cf ammonia under assay conditions. All samples were measured at 30 0 C, using either the SPECTRAFluor Plus or the Sunrise (both from TECAN) reader for microplates. Kinetic data was evaluated using GraFit software. Inhibitor assay For inhibitor testing, the sample composition was the same as described above, except of the putative inhibitory compound added. For a rapid test of QC-inhibition, samples contained 4 mM of the respective inhibitor and a substrate concentration at 1 Km. For detailed investigations of the inhibition and determination of Krvalues, influence of the inhibitor on the auxiliary enzymes was investigated first. In every case, there was no influence on either enzyme detected, thus enabling the reliable determination of the OC inhibition. The inhibitory constant was evaluated by fitting the set of progress curves to the general equation for competitive inhibition using GraFit software. Example 3: MALI-TOF mass spectrometry Matrix-assisted laser desorption/ionization mass spectrometry was carried out using the Hewlett-Packard G2025 LD-TOF System with a linear time of flight analyzer. The 58 instrument was equipped with a 337 nm nitrogen laser, a potential acceleration source (5 kV) and a 1.0 m flight tube. Detector operation was in the positive-ion mode and signals were recorded and filtered using LeCroy 9350M digital storage oscilloscope linked to a personal computer. Samples (5 p) were mixed with equal volumes of the matrix solution. For matrix solution we used DHAP/DAHC, prepared by solving 30 mg 2',6'-dihydroxyacetophenone (Aldrich) and 44 mg diammonium hydrogen citrate (Fvuka) in 1 ml acetonitrile/0.1% TFA in water (1/1, v/v). A small volume (= 1 pl) of the matrix-analyte-mixture was transferred to a probe tip and immediately evaporated in a vacuum chamber (Hewlett-Packard G2024A sample prep accessory) to ensure rapid and homogeneous sample crystallization. For long-term testing of Glu'-cyclization, Ap-derived peptides were incubated In 100pl 0.1 M sodium acetate buffer, pH 5.2 or 0.1 M Bis-Tris buffer, pH 6.5 at 30 0 C. Peptides were appsed in 0.5 mM [A03-11a] or 0.15 mM (A03-21a] concentrations, and 0.2 U 0C was added all 24 hours. In case of Ap3-21 a, the assays contained 1 % DMSO. At different times, samples were removed from the assay tube, peptides extracted using ZipTips (Millipore) according to the manufacturer's recommendations, mixed with matrix solution (1:1 v/v) and subsequently the mass spectra recorded. Negative controls did either contain no QOC or heat deactivated enzyme. For the inhibitor studies the sample composition was the same as described above, with exception of the inhibitory compound added (5 mM benzimidazole or 2 mM 1,10-phenanthroline). Example 4: pH dependence The pH-dependence of catalysis of human and papaya QC was investigated under first-order rate conditions, thus reflecting the impact of the proton concentration on the specificity constant keVKm. For this purpose, the coupled enzymatic assay using pyroglutamyl aminopeptidase as auxiliary enzyme and Gin-#iNA as substrate was used. Pyroglutamyl aminopeptidase was shown to be active and stable between pH 5.5-8.5 (Tsuru, D. et al. 1978 J Biochem (Tokyo) 84, 467-476). Hence, the assay enabled the study of OC catalysis in this pH-region. The rate profiles obtained were 59 fit to classical bell shaped curves, as shown in Figure 2. The human OC bears a very narrow pH-dependence with an optimum at about pH 7.8-8.0. The rate tended to decrease at more basic pH. This is in contrast to the rate profile observed with papaya QC, which showed no drop in activity up to pH 8.5 (Figure 2, inset). However, both enzymes had their optimum of specificity at pH 8. Surprisingly, evaluation of the curves revealed identical pKa-values in the acidic range of 7.17 ±0.02 and 7.15 ±0.02 for human and papaya OC, respectively. The reduction of the activity of human OC at basic pH-values was obviously due to dissociation of a group with a pK.a of approximately 8.5. In case of papaya OC, there was no excessive data point collection in the basic pH-range possible to enable a reliable determination of the second pKa value. This is supported by fitting of the data to a single dissociation model, resulting in an almost identical pK-value (pKa 7.13 ±0.03) compared to fitting the data to a double disssociation model. This indicates that both pKa-values are fairly separated.. PH stability The stability of the glutaminyl cyclases was investigated by incubating the plant and animal enzymes at 30 0C for 30 min at different pH values between pH 4-10. Afterwards, OC activity was determined under standard conditions. The results are shown in Figure 3. The QC from papaya latex was stable in the pH-range studied, without an obvious trend for instability in the acidic or basic range. In contrast, human OC only showed a comparable stability in the pH-range between 7 and 8.5, exhibiting a remarkable instability at pH values above pH 8.5 and below pH 6. Thus, the region around pH 8 seems to be optimal for activity and stability of plant and human QC and a suitable pH-value for performing a substrate specificity comparison of the QCs. Example 5: Determination of substrate specificity of QC 60 Spectrophotometric assay The continuous spectrophotometric assay was performed as described in example 2. Accordingly, OC activity is reflected by a decrease in absorbance at 340 nm caused by the ammonia release and subsequent consumption of NADH/H* due to formation of glutamate from c-ketoglutaric acid. As shown in Figure 1, linear progress curves were monitored and there was a linear relationship between the measured activity and the concentration of QC. Furthermore, the kinetic parameters obtained for H-Gin Gin-OH using the continuous assay presented here (Table 1) were in good agreement with those obtained using the discontinuous method (Km= 175 ±18 pM, kcat= 21.3 ±0.6 s-). In addition, the kinetic parameters for conversion of the substrates H-Gln-Ala-OH, H-Gln-Glu-OH, H-GIn-GIn-OH, H-Gln-OtBu and H-GIn-NH 2 by papaya 0C shown in Table 1 correspond well to those determined using a direct method at pH 8.8 and 37 *C (Gololobov, M. Y. et al. 1996 Biol Chem Hoppe Seyler 377, 395-398). Hence, it is quite obvious that the novel continuous assay provides reliable results. Di-, Tri- and Dipepftide-surrogates Utilizing the novel continuous assay described above, about 30 compounds were tested as potential substrates of 0C from C. papaya and human. The results are displayed in Table 5. By comparison of the specificities it was shown, that nearly all of the short peptide substrates are more efficiently converted by papaya QC compared to the human enzyme. Interestingly, for both enzymes substrates with large hydrophobic residues in the second position are the most potent ones, as shown by the specificities of H-Gln-Tyr-Ala-OH, H-Gln-Phe-Ala-NH 2 and H-Gln-Trp Ala-NH 2 compared to those of other tripeptides or by the reactivities of the chromophoric substrates H-GIn-AMC, H-Gln-pNA and H-GIn-Tyr-OH in comparison to dipeptide substrates. For papaya 0C, this finding is in agreement with earlier results showing tha: the specificity is in correlation with the size of the second amino acid residue (Gololobov, M. Y. et al. 1996 Biol Chem Hoppe Seyler 377, 395-398). The only striking difference in specificity of the plant and animal QC was observed in case of H-GIn-OtBu . Whereas the ester was converted by papaya 0C with similar 61 specificity compared to dipeptide substrates, it was converted about one order of magnitude slower by human QC. Oligopeptides Besides several dipeptides and tripeptides, a number of oligopeptides was tested upon conversion by papaya and human OC (Table 5). Interestingly, the overall difference in the specificities between human and plant 0C for a set of tetrapeptides was not that large as it was observed for dipeptide and tripeptide substrates. This indicates that the amino acids in the 3'd and 4* position still affect the kinetic behavior especially of human QC. An exception, however, comprise the peptides with a proline residue in the second amino acid position which show noticeably reduced kcat/KM values in a set of tetrapeptides of the structure H-Gln-Xaa-Tyr-Phe-NH 2 (Table 5). The reduction in specificity was more pronounced for human QOC, leading to an approximately 8-fold difference in the kca/KM-value as compared to papaya QC. Slightly reduced specificities of human QC were also observed for conversion of substrates with a positively charged amino acid C-terminal of glutamine, as indicated by the specificities for H-Gln-Arg-Tyr-Phe-NH 2 , H-Gln-Arg-Tyr-Phe-NH 2 and H-GIn Lys-Arg-Leu-NH 2 as compared to other tetrapeptides. Apparently, the reduced specificity was mainly due to a smaller turnover number. This effect was not the case for the plant enzyme. Table 5: Kinetic evaluation of peptide substrates of human and Papaya QC (n.r., not reactive; n.l., no Inhibition; n.d., not determined; *, for substrate inhibition) Substrate Human OC Papaya QC Ka (pM) kad Ki* k../Ku K.* (pM) kad Ka' k../u (s'')_ (mM) )(mw' 6) " (MML (mM'' s'') H-Gn-OH n.r. n.r. n.d. n.r. n.d. n.d. 0.23 ±0.1 H-Gin-AMC 54±2 5.3±0.1 n.d. 98±2 42 ±1 39.4 ±0.4 n.d. 938 ±13 H-Gln-#NA 70 ±3 20.6 ±0.5 1.21 ±0.07 294 ±6 38 ±3 51.4 ±1.4 1.20±L0.08 1353 ±70 H-GIn-Ot~u 1235±74 6.7±0.2 nl. 5.4±0.2 223 ±9 49.4 ±0.6 nMl. 222 ±6 62 H-GIn-NH 2 409 t40 12.8 ±0.5 n.L 31 ±2 433 t13 44.8t0.4 n.f. i132 H-Gin-Gly-OH 247 ±10 13.2 ±0.2 n.i. 53±1 641 ±20 45.60.4 n.i. 71 2 H-GIn-Ala-OH 232 ±5 57.2 t0.4 n.i. 247 ±4 158t8 69.8 11.0 n.L. 442 *18 H-Gin-Gin-OH 148 ±5 20.7 ±0.2 n.l. 140 ±2 44 ±3 43.2 ±0.7 n.i. 982 ±51 H-GIn-GIu-OH 359 ±10 24.7±0.2 n.l. 58±t1 106 ±5 50.3±0.6 n.j. 475 ±17 H-Gin-VaJ-OH 196 ±5 17.2 ±0.1 n.j. 88 2 n.d. n.d. n.I. n.d. H-Gin-Tyr-OH 211 ±5 94 ±1 n.j. 446±6 n.d. n.d. n.I. n.d. H-GIn-GIu-Tyr-NH : 79 ±2 45.1 10.4 n.I. 524±8 103 ±4 53.6 t0.7 n.j. 520 ±13 H-Gin-Gly-Pro-OH 130 ±5 25.3 ±0.2 n.j. 195 ±7 333 ±15 41.7 ±0.5 n.i. 125 ±4 H-GIn-Tyr-Ala-OH 101±4 125±1 n.j. 930±27 63±3 104.0 ±1.0 n.. 1650±63 H-Gin-Phe-Ala--NHi 69±3 109 1 n.I. 1811 ±64 111 ±5 132.1 ±0.6 n.. 1190±48 H-GIn-Trp-Ala-NH2 50 t2 47.0 ±0.7 n.h. 940 ±24 78 ±5 151.8 ±2.6 n.j. 1946 t91 H-GIn-Arg-GIy-Ile-NH 2 143 ±4 33.5±10.4 n.L 234 ±4 123 ±10 49.2 ±1.7 n.i. 400 ±19 H-Gln-Asn-Gly- He-NH2 172 ±5 56.6 50.5 n.j. 329 ±7 153 ±9 51.4 ±0.9 n.j. 336 ±14 H-Gln-Ser-Tyr-Phe-NHz 55 ±3 52.8 ±0.8 n.I. 960 ±38 135 ±6 64.9±1.0 n.j. 481 ±14 H-GIn-Arg-Tyr-Phe-NHz 55 t2 29.6 t0.3 n.j. 538 ±14 124 ±6 48.9 ±0.7 n.l. 394 ±13 H-Gin-Pro-Tyr-Pho-NH2 1889 ±152 31.7 ±1.2 n.I. 17 ±i 149±t14 18.8±0.6 n.j. 126 ±8 H-Gin-His-Tyr-Phe-NH: 68 ±3 55.4+t0.7 n.j. 815 126 92 ±7 75.9 ±1.4 n.i. 825 :48 H-GIn-GIn-Tyr-Phe-NH2 4112 41.4±0.4 n.j. 1010±40 45±2 52.9±0.7 n.I. 1176±37 H-Gin-Glu-Tyr-Phe-NH 2 47 ±4 46 ±1 n.. 979 ±62 100 t4 54.6 ±0.6 n.. 546 ±16 H-GIn-GIu-AIa-AIa-NH2 77 ±4 46 ±1 n.j. 597 ±18 102 ±4 53.7 ±0.6 n.L. 526 ±15 H-GIn-Glu-Tyr-Ala-NH2 69 ±2 42.11±0.4 n.j. 610 ±12 113±5 44.7 ±0.5 n.j. 396 ±13 H-Gin-Glu-Ala-Phe-NHa 39 ±3 39 ±1 n.j. 1000 ±51 81 t3 48.5 ±0.45 n.j. 599 17 H-Gin-Glu-Asp-LeU-NHa 55 ±2 45.8 ±0.5 n.. 833 ±21 107 ±6 58.5 ±0.4 n.j. 547 ±27 H-Gln-Lys-Arg-Leu-NH2 54 ±3 33.4 ±0.5 n.. 619±25 118 ±6 48.2 ±0.8 n.j. 408 ±14 The results obtained with the tetrapeptides give also rise to another conclusion. As already pointed out, papaya OC showed a higher selectivity for dipeptides. For some of the tetrapeptides, however, higher specificity-constants were observed with human QC, as shown in Figure 4 providing a plot of the data given in Table 5, for a set of peptides containing glutamate in the second amino acid position. Furthermore, as the chain length increases from di- to tetrapeptides, the selectivity of human QC increases, in contrast to the results obtained with papaya QC. Additionally, the highest selectivity of human QC was recorded for the peptides containing bulky hydrophobic residues in the 3r and 4t' amino acid position, which indicate hydrophobic interactions with the enzyme. By comparison of the kinetic parameters for the respective peptides, the changes seem to be mainly due to lower KM-values, the tumover numbers for conversion of the peptides were found to be similar. Thus, the higher selectivity of human OC for longer peptides is considered to be the result of tighter binding of the more hydrophobic substrates to the enzyme.
63 The differences between human and plant QC observed with peptides containing hydrophobic amino acids in the 3d and 4 t' position becomes also evident by a comparison of the specificity constants of the enzymes towards H-Gln-Arg-Gly-Ile
NH
2 and H-Gin-Arg-Tyr-Phe-NH 2 or H-Gin-Gln-OH and H-Gin-Gln-Tyr-Phe-OH. Human QC was also found to be more selective for homologous substrates containing N-terminal Gin and an increasing number of C-terminal Ala residues (Table 6). While the selectivity of human 0C increased with substrate length, there was no such a trend with the papaya QC. Since human QC was less specific for a peptide containing a Ser residue in the sequence, also the nature of the side chain seems to be of importance (table 6). Table 6: Influence of substrate length on the activity of human and Papaya OC Substrate Human OC Papaya oc K, (M) k.. k.JK K (pM) k.m k.dKm (s'') (mM'' ('') (s-') (mM'' S'') H-GIn-Aa -NH 2 155±9 40.1 ±0.9 259±9 212±21 62.8±3.0 296±15 H-Gin-Ala-Ala-NH:: 87 ±3 76.3 ±0.7 877 ±22 164±6 83.2 ±1.0 507 ±12 H-GIn-Ala-Aa-Aa-aAla-NH2 65±3 60.51±0.7 1174143 197 ±8 74.6 ±1.0 379±10 H-GIn-AJa-Ala-Ser-Ala-Ala-NH 2 79±6 55.3 ±1.6 700 ±33 216 ±6 78.5 ±1.0 363t5 Influence of ionic strength on catalysis Another parameter that was investigated concerning its influence on the substrate specificity was ionic strength. For that purpose, the kinetic parameters for cyclization of several substrates were determined in presence and absence of 0.5 M KCI (Table 7). Surprisingly, the selectivity for substrates with uncharged backbone did not change significantly by addition of the salt in case of QC from papaya latex and human QC. The specificity constants of the human OC for H-GIn-Ala-OH and H-GIn Glu-OH, however, decreased by addition of KCI. As indicated by the individual kinetic parameters, this effect was due to an increasing KM and an only slightly decreasing karvalue. In case of papaya QC, there was no effect on either parameter detected. The effect seemed not to be due to the negatively charged substrate as such, since 64 unchanged parameters were found for the negatively charged peptide H-Gln-Glu Asp-Leu-NH 2 . An interesting effect of the salt addition was found for the positively charged substrates H-Gln-Arg-Gly-lle-NH 2 and H-Gln-Lys-Arg-Leu-NH 2 . In case of plant and human QC, a positive effect on catalysis was determined mainly due to a smaller KM value and a slightly higher turnover number. Table 7: Influence of Ionic strength on catalysis of human and Papaya OC Substrate 0.05 M Tricine-NaOH, pH 8.0 0.05 M Tricne-NaOH, pH 8.0, 0.5 M KCI KM (mM) k (s' keKM K (mM) Km k. (s') ke.KM Ki ') (mMs'') (mM) (mM''s'') (mM) H-GIn-NH 2 0.434 43.4 100 ±3 n.l. 0.446 45.2 101 ±2 n.L ±0.015 ±0.4 ±0.010 10.3 H-GIn-#NA 0.036 48.8 1356 ±50 1.14 0.032 47.2 1475 ±70 1.33 +0.002 ±1.0 ±0.05 1±0.002 ±0.8 +-0.07 H-GIn-AJa-OH 0.137 69.7 509±19 n.1. 0.143 68.1 480±12 nl.L 8 0.007 ±.9 I ±0.005 ±0.6 I e H-Gin-Glu-OH 0.098 45.0 459 ±18 n.1. 0.094 44.4 472 ±12 n.L ±0.005 ±0.5 ±0.003 ±0.3 e H-Gln-Trp-Ala-NH 2 0.079 138 ±3 1747 ±73 n.L 0.072 133±3 1847161 n.L _________ ±0.005 +±0.004 H-Gln-Arg-Gly-lIe-NH 2 0.106 52.9 499 ±26 n.l. 0.065 48.4 745 ±42 n.L ±0.008 ±1.2 ±0.005 ±1.0 I H-Gin-Lys-Arg-Leu-NHz 0.102 50 ±1 493 t22 n.L 0.053 58.1 1096 ±28 n.1. +-0.007 ±0.002 ±0.7 H-GIn-Glu-Asp-L.eu- 0.109 52.4 481 ±16 n.L. 0.094 53.8 570 ±13 n.j.
NH
2 ±0.005 0.7 0.003 0.5 0.05 M Tris HCI, pH 8.0 0.05 Tris-Hc1 pH 8.0,0.5 M KcI H-GIn-NH 2 0.442 12.8 29W1 n.1. 0.401 12.2 30±1 n.L ±0.030 ±0.3 ±0.014 ±0.1 H-Gln-fNA 0.076 21.7 285±8 1.39 0.063 20.0 318 ±9 0.97 ±0.004 ±0.5 ±0.08 ±0.003 ±0.4 ±0.04 H-GIn-Ala-OH 0.269 54.4 2023 n.L 0.357 47.6 133±3 n.L ±0.007 ±0.5 I ±0.012 ±0.6 8 H-Gln-Glu-OH 0.373 21.4 57±2 n.L 0.607 18.9 31 ±1 n.L +-0.015 ±0.3 ±0.038 ±0.5 5 H-GIn-Trp-Ala-NHa 0.054 50.8 941 ±41 n.1. 0.058 50.0 893±25 n.L ±0.003 ±0.8 _ ±0.002 ±0.4 H-GIn-Arg-Gly-lIe-NH 2 0.166 31 ±1 187 ±9 n.1. 0.091 29.8 327 *12 nl. ±0.013 ±0.005 ±0.5 H-GIn-Lys-Arg-Leu-NH 2 0.051 29.4 577±24 n.1. 0.034 31.6 929 ±19 n.. ±0.003 ±0.5 0.001 ±0.3 H-Gn-Glu-Asp-.9u- 0.060 46.6 777 ±18 n.L. 0.061 46.6 748 ±16 n.L
NH
2 ±0.002 ±0.5 ±0.002 ±0.5 I Physiological substrates In earlier studies, conversion of [Gln']-TRH and [GIn]-GnRH by 0C was already shown for the 0C trom bovine and porcine pituitary (Busby, W. H. J. et al. 1987 J 65 Biol Chem 262, 8532-8536; Fischer, W. H. and Spiess, J. 1987 Proc Natl Acad Sci U S A 64, 3628-3632). In addition to these already investigated pituitary hormones, three potential physiological substrates of human QC were synthesized and tested upon conversion, namely [Gln')Gastrin, [GIn']Neurotensin, and [Gln']FPP. The kinetic parameters for their conversion are listed in Table 1. Interestingly, the glutaminyl peptides are converted to the respective pyroglutamyl peptides with increasing specificity constants depending on their size, i.e., the first largest peptide pro-gastrin with 17 amino acids followed by pro-neurotensin, pro-GnRH, pro-TRH and pro-FPP. These findings correspond to the data obtained with the synthetic peptides. Surprisingly, the longer substrates are also converted with higher selectivity by the plant enzyme, a result that contrasts in part with the findings for the shorter oligopeptides. Possibly, there are secondary binding interactions between substrate and enzyme far distant from the active site. Peptides comprisinq modified amino acids In order to further investigate the specificity and selectivity of the QCs, peptides were synthesized comprising either a modified N-terminal glutaminyl residue or a modified amino acid in the second position. The conversion of these peptides was investigated qualitatively utilizing MALDI-TOF mass spectrometry (see also example 3). Due to the cyclization of the glutaminyl residue or its analog, respectively, a mass difference of the substrate and the product of catalysis Is detected. In cases of ammonia liberation of one mole per mole of substrate, the conversion was also analyzed quantitatively using the spectrophotometric assay. H-GIn-Lys(Gin)-Arg-Leu-Ala-NHz. This N-terminally branched peptide, comprising two glutaminyl residues at the N-terminus that are bound to a lysyl residue via a peptide- and partial isopeptide bond, was converted by human (Figure 5) and papaya OC (not shown) in an apparently identical manner. Both glutaminyl residues were converted into pyroglutamic acid, without any detectable preference for a distinct residue, as indicated by the consistent substrate conversion (Figure 5).
66 Thus, the selectivity of the OCs for the differently bound glutaminy residues differs not fundamentally. H-Gin(NMe)-Phe-Lys-Ala-Gu-NH 2 . The methylated glutaminyl residue was only converted into a pyroglutamyl residue by papaya OC (Figure 6). Additionally, an inhibition of the human QC by the peptide was not detected, indicating that the methylated residue is not recognized by human OC. H-Glu(OMe)-pNA and H-Glu-PNA. Neither of these compounds were converted by papaya or human QC. These fluorogenic substrates were analyzed fluorometrically, utilizing pyroglutamyl aminopeptidase as auxiliary enzyme. The 0 methylated glutamate residue, however, showed a remarkable instability in both, Tris and Tricine bulfers tending to a non-enzymatically catalyzed cyclization. Furthermore, activity of both QCs against H-Gln-AMC as substrate was not inhibited by the longer peptides H-Glu(OMe)-Phe-Lys-Arg-Leu-Ala-NH 2 or H-Glu-Phe-Lys-Arg Leu-Ala-NH 2 , indicating that glutamic acid or derivates are not recognized by both OC forms. Furthermore, the result implies that not only the negative charge of the glutamic acid residue is the reason for the repulsion of the peptide from the active site. H-Gln-cyclo(Ne-Lys-Arg-Pro-Ala-Gly-Phe). The conversion of H-Gln-cyclo(Ne Lys-Arg-Pro-Ala-Gly-Phe), which contains an intramolecular partial isopeptide bond was analyzed quantitatively, revealing Km-values of 240 ±14 pM and 133 ±5 pM for human and papaya QC, respectively. Due to the higher turnover number of conversion by papaya QC (49.4 ±0.6 s"') compared to human QC (22.8 ±0.6 s-'), the plant enzyme exhibits with 372 ±9 mM' min" an approximately 4-fold higher kedKm value than the hurnan QC. Thus, the specificity constant is in case of the papaya OC only slightly smaller compared to substrates having a similar size, such as H-Gin-Ala Ala-Ser-Ala-Ala-NH 2 . The kodK-value for human QC, however, was found with 95 ±3 mMIs-' to be approximately one order of magnitude smaller in comparison with substrates of similar size (Table 5).
67 H-phomoGIn-Phe-Lys-Arg-Leu-Ala-NH 2 . The N-terminal 0-homoglutaminy residue was converted into a five-membered lactam ring by catalysis of human and papaya 0C, respectively. The concomitant liberation of ammonia was analyzed spectrophotometrically and by MALDI-tof analysis as described before. There was no liberation of ammonia detected when QC was omitted or boiled, indicating a specific catalysis of the cyclization. Interestingly, the 0C from C. papaya (Km= 3.1 ±0.3 mM, kot= 4.0 ±0.4 s') and human (Km= 2.5 ±0.2 mM, kct= 3.5 ±0.1 s') catalyze the conversion of this peptide with almost identical km/Km values of 1.4 ±0.1 and 1.3 ±0.1 mM' 1 s', respectively. Thus, the cyclization of the 0-homoglutamine residue is catalyzed with an approximately 1000-fold reduced efficiency compared to peptides of similar size containing a glutaminyl residue at their N-terminus. This shows that the constitution of the a-carbon of the substrate is important for substrate recognition by the QC forms, but not essential. The essential requirement for being a substrate is a y-amide group and an unprotonated N-terminal amino group in distance and angle prone for cyclization, a requirement that is fulfilled by N-terminal glutaminyl and p homo-glutaminyl residues.
68 Example 6: Synthesis of the QC substrates Oligopeptides. Peptides were synthesized semiautomatically in 0.5 mmol scale using a peptide synthesizer (Labortec SP650, Bachem, Switzerland) as previously described (Schilling, S. et al. 2002 Biochemistry 41, 10849-10857). Longer peptides were synthesized in 25 Imol scale using the automated Symphony peptide synthesizer (Rainin Instrument Co.) as described (Manhart, S. et al. 2003 Biochemistry 42, 3081-3088). For all peptide couplings modified Fmoc-protocols of solid-phase peptide synthesis were employed using 2-(1 H-Benzotriazole-1 -yl) 1,1,3,3,-tetramethyluronium tetrafluoroborate (TBTU; Novabiochem)/base (diisopropyl ethylamine or N-methyl- morpholine; Merck) or in case of difficult couplings N-[(Dimethylamino)-1 H-1,2,3,-triazolo[4,5-b]pyridin-1 -ylmethylene]-N methylmethanamminium hexafluorophosphate N-oxide (4,5) (HATU; Applied Biosystems)/ diisopropyl ethylamine as activating reagents were used. After cleavage from the resin by trifluoroacetic acid (TFA; Merck) containing cocktail, the crude peptides were purified by preparative HPLC with acid free solvents in order to avoid further cyclization of the N-terminal glutamine. Preparative HPLC was performed with a linear gradient of acetonitrile (Merck) in water (5-40 % or 65 % acetonitrile over 40 min) on a 250-21 Luna RP18 column (Phenomenex). To confirm peptide purity and identity analytical HPLC and ESI-MS was employed. Glu{NH-NH2)-Ser-Pro-Thr-Ala-NH 2 . The linear precursor peptide (Fmoc-Glu Ser-Pro-Thr-Ala-NH 2 ) was synthesized according to standard Fmoc-procedures (Schilling, S. et al. 2002 Biochemistry 41, 10849-10857) on Rink amide MBHA resin (Novabiochem). After cleavage of the Fmoc-protected peptide from the resin, the peptide was precipitated with diethyl ether (Merck), filtered and dried. HMBA-AM resin (1.16 mmol/g, Novabiochem) was used for coupling of the y-carboxylic acid group of glutamic acid of the precursor peptide (3 eq.) in dichloromethane (DCM, Merck). Dicyclohexylcarbodiimide (DCC, Serva) (4 eq.) and dimethylaminopyridine (DMAP, Aldrich) (0.1 eq) were used as coupling reagents. After 12 hours the resin was filtered, washed with DCM and the reaction was repeated. After deprotection of the N-terminal Fmoc-group by employing 20% piperidine in DMF (3 x 5 min) the 69 peptide resin was treated with a 5% hydrazine solution (20 m/g) for 1.5 hours. The resin was filtered and washed with dimethylformamide (DMF, Roth, Germany) and TFA. Following evaporation, the crude peptide was precipitated with ether giving 76 % yield. H-Gln-Lys(Cin)-Arg-Leu-Ala-NH. The linear peptide was synthesized according to standard Fmoc/'Bu-procedure on Rink amide MBHA (Schilling, S. et al. 2002 Biochemistry 41, 10849-10857) using Fmoc-Lys(Fmoc)-OH as penultimate amino acid coupling. After deprotection of the two amino protecting groups of lysine with 20 % piperidine (Merck) in DMF, 4 eq. Fmoc-Gln(Trt)-OH were coupled. Standard cleavage procedure resulted in 95% yield. H-GIn(NMei-Phe-Lys-Ala-Glu-NH. Fmoc-GIn(NMe)-OH was synthesized starting from Fmcc-Glu-OtBu loaded on Fmoc-MI-AM (Novabiochem) resin. After swelling with DCM, the resin (0.5 g) was washed with DMF and deprotected with 20% piperidine solution in DMF. The resin was given into 5 ml DMF and 5 eq. Fmoc Glu-OtBu, 5 eq. HATU and 10 eq. DIPEA were added subsequently and shaked for 6 hours. After filtration and washing, the product was cleaved according to standard TFA cleavage conditions. The peptide H-Gln(NMe)-Phe-Lys-Ala-Glu-NH2 was synthesized as described (Schilling, S. et al. 2002 Biochemistry 41, 10849-10857). Fmoc-Gln(NMe)-OH was coupled with HATU/DIPEA overnight. Standard cleavage procedure resulted in 78% of the crude peptide. H-GIu(OMe)-p-naphthylamide, H-Gin-Val-OH, H-Gln-Tyr-OH. Boc-protected dipeptides were synthesized applying standard mixed anhydride procedure by using isobutyl chlorocarbonate (Merck). The C-terminal methylesters Boc-GIn-Tyr-OMe and Boc-GIn-Val-OMe were saponified by 1 N NaOH in dioxane. The Boc-protected peptides were deprotected by HCVdioxane solution for 10 min. After evaporation the residue was crystallized with several solvents giving 60-70% of a solid compound. H-Gln-cyclo(Ne-Lys-Arg-Pro-Ala-Gly-Phe). The linear precursor Boc-Gln(Trt) Lys-Arg(Pmc)-Ala-Gly-Phe-OH was synthesized on acid sensitive 2-chlorotrityl resin.
70 Coupling was carried out using a standard protocol of Fmoc/'Bu-strategy using Fmoc Lys(Mtt)-OH. Aftor cleavage with 3% TFA solution in DCM (10 times 5 min), the solution was neutralized with 10% pyridine (Merck) in methanol (MeOH; Merck), washed 3 times with DCM and MeOH, evaporated to 5 % of the volume and the crude peptide was precipitated with icecold water. Following, the crude peptide was cyclized using DCC/N-hydroxybenzotriazole (HOBt; Aldrich) activation. The crude peptide was dissolved in dry dichloromethane (0.2 mmol/50 ml), 0.2 mmol N methylmorpholinE and 0.4 mmol 1-hydroxybenzotriazole were added. This solution was added dropwise to a solution of 0.4 mmol dicyclohexylcarbodiimide in 250 ml dichloromethane at 0*C. The reaction was completed by stirring overnight at room temperature. After filtration of N,N'-dicyclohexylurea, the solvent was removed by evaporation. The residue was dissolved in ethyl acetate and washed several times with 1N HC, saturated solution of NaHCO 3 and water. The solution was dried over anhydrous Na 2
SO
4 , filtered and evaporated to dryness in vacuo. Example 7: Characterization of effectors of OC Imidazole derivatives Imidazole and benzimidazole derivatives carrying substituents in different positions of the 5-membered ring were tested as inhibitors of OC (Table 3). The constitution of the numbers refers to the imidazole ring. The applied methods are described in example 2. C-4(5) and C-4,5 derivatives. The compounds carrying substitutions in either in the constitutionally equivalent 4- or 5- position of the imidazole ring or in both positions showed a diminished potency for inhibition of human QC. The only exception, however, comprised N-w-acetylated histamine that proved to be one of the most potent inhibitory compounds. Small substituents in these positions had only little effect on binding as indicated by the similar inhibition constant of 5-hydroxymethyl-4 methyl-imidazole compared to imidazole. Larger and more bulky groups attached to 71 these sites diminished or abolished binding of the compound by the enzyme. Some of the other substituents tested are known to exert negative inductive or mesomeric effects that are capable to reduce the electron density in the imidazole ring, which also contributes to poorer binding constants. The difference in the Kr-values of L histidine and histidinamide also indicate some influence of the charge on binding. Evidence for electrostatic repulsion of charged substrates were already shown in the substrate specificity studies, i.e. glutaminamide was readily converted to products by human QC, but nc reactivity was observed for free glutamine as substrate. C-2 derivatives. All derivatives tested inhibited QC more weakly as imidazole. Any substitution bigger than a proton hinders proper QC-binding. Only due to the methyl group in 2-methyl-benzimidazole, the inhibition constant drops about one order of magnitude. A very similar relation was shown by comparison of the Kr-values for benzimidazole and 2-amino-benzimidazole. Additionally, the results indicate that the influence is not related to electronic alterations. N-1 derivatives. Among the imidazole derivatives tested on inhibition of human QC, most compounds that had improved Kr-values compared to imidazole showed alterations at one nitrogen atom. These compounds also contained one of the most effective QC inhibitors, 1-benzylimidazole. Interestingly, only little alterations of this structure led to a loss of inhibitory quality, as can be seen for 1 -benzoylimidazole and phenylimidazole, which was inactive under the experimental conditions. Also In this case, the observed changes seemed not to be only caused by a reduced electron density of the imidazole ring due to the negative mesomeric effect of the Phenyl group, because also the bulky trimethyl-silyl group, exhibiting a positive inductive effect showed reduced binding compared to other residues. Interestingly, one of the less effective compounds of this group was 1-aminopropyl-imidazole. The small efficacy of this compound is caused by the basic amino group, since the sterically similar compounds 1 -methylimidazole and 1 -vinylimidazole showed improved binding to the active site. Thus, the positively charged amino group accounts for the smaller Kr-value, a result that is corroborated by a comparison of the 1 -values of N-o acetylated histamine (Table 3) and histamin (Table 4).
72 Effect of 3,4 and 3,5 derivatization. The imidazole derivatives that contained substituents in postions 4(5) or both were shown to have a restricted efficiency for binding to the enzyme. The effect of the specific substitutions were specified by comparison of the inhibitory constants of L-histamine and the two intermediates in the biological degradation of histamine, 3-methyl-4-histamine and 3-methyl-5-histamine (Table 4). L-Histamine revealed a Ki value that was about one order of magnitude smaller compared to its acetylated counterpart. Methylation of one nitrogen resulted in a considerable improvement of efficacy in case of 3-methyl-4-histamine. Methylation leading to 3-methyi-5-histamine, however, resulted in a complete loss of inhibitory activity. Thus, the observed effect seems to be mainly caused by a sterical hindrance of binding due to the derivatisation of the carbon adjacent to the basic nitrogen. Presumably, the basic nitrogen plays a key role for binding to the enzyme. Example 8: Formation of Ap3-40/42 derivatives The measurements were carried out with two short N-terminal peptide sequences of A03-40/42, [Gin 3 )-Ap1-11 (sequence: DAQFRHDSGYE) and [Gin 3 ]Ap3-1 1, which contain a glutarmine instead of an glutamic acid residue in the third position. Cleavage by DP IV and cyclization of the N-terminal glutamine residue by QC of the two peptides was tested using MALDI-TOF mass spectrometry. Measurements were carried out using purified DP IV (porcine kidney) or crude porcine pituitary homogenate as sources of OC as well as for both enzymes for measurements of consecutive catalysis. Results 1. Formation of [Gin 3 ]AP3-11a from [GIn 3 ]AP1-11a catalysed by DPIV and its prevention by the DP IV-inhibitor Val-Pyrrolidide (Val-Pyrr) DPIV or DPIV-like activity is cleaving [GIn]AO1-11 a under formation of [Gin 3 ]AP3-1 1a (Figure 7). The residue in the third position is uncovered by this cleavage and 73 becomes therefore accessible for modification by other enzymes, i.e. QC. As expected, catalysis can be completely prevented by Val-Pyrr (Figure 8). 2. Formation of [pGL]Ap3-1 la from [Gln 3 JAP3-1 1a by catalysis of QC in pituitary homogenate and prevention by 1, 10-phenanthroline Glutaminyl cyclase present in the homogenate of porcine pituitary catalyzes conversion of [Gin 3 ]AS3-1 1a to [pGlu 3 ]AP3-1 1a (Figure 9). Formation of [pGlu 3 ]Ap3 11 a was inhibited by addition of 1,1 0-phenanthroline (Figure 10). 3. Consecutive catalysis of DPIV and OC resulting in formation of [pGlu]Afi3-1 la and prevention by Val-Pyrr and 1,10-phenanthroline Formation of (pGlu 3 ]AP3-11a from [Gln 3 ]A01-11a takes place after consecutive catalysis by DP IV and OC, measured in crude homogenate of porcine pituitary with added DPIV from porcine kidney (Figure 11). [pGlu 3 ]Ap3-1 1a was not formed when the OC-inhibitor 1,10-phenanthroline (Figure 12) or the DP IV-inhibitor Val-Pyrr was added (Figure 13). The slight appearance of [pGlu 3 ]A53-1 1a is due to aminopeptidase cleavage and following cyclization of the glutamine residue, also indicated by formation of [Gln 3 ]Ap2-1 1 a. 4. Formation of {pGlu'3]A3-11 Ia in crude pituitary homogenate by catalysis of aminopeptidase(s) Due to the formation of [pGlus]Ap3-1 1 a that was not dependent on DPIV catalysis, degradation of [Glri 3 Ap 1 -11 a was investigated in crude pituitary homogenate without added DPIV (Figure 14). As expected from the data in section 4, formation of (pGlu 3 ]A03-1 1a was observed. The data show that the degradation of [Gin]AP1-11 a may also be catalyzed by aminopeptidase(s), resulting in [pGlu 3 ]AP3-1 1a. Hence, the results show that pyroglutamyl formation is an endpoint of N-terminal peptide degradation in this tissue, further supporting the role of QC in plaque formation.
74 Example 9: Turnover of [GIn]Ap3-11a; 3-21a and 3-40 by recombinant human QC All [Gln 3 ]As derived peptides tested were efficiently converted by human QC into the corresponding pyroglutamyl forms (Table 8). Due to the poor solubility of [Gin 3 ]A3 21a and [Gln 3 ]Ap3-40 in aqueous solution, the determinations were carried out in presence of 1% DMSO. The better solubility of [Gin 3 ]Ap3-1 1 a, however, allowed the kinetic analysis of the QC-catalyzed turnover in presence and absence of DMSO (Table 8). Taken together, the investigation of the As peptides as QOC-substrates with chain-length of 8, 18 and 37 amino acids (see Table 8) confirmed the observation that human 0C-activity increases with the length of its substrates. Accordingly, Gin' gastrin, Gin'-neurotensin, Gln'-GnRH are among the best OC-substrates taking the specificity constants into account. Similarly, [GIn 3 ]Ap3-40 and glucagon, the largest QC-substrates investigated thus far, exhibited high second order rate constants (449 mM-ls'l and 526 rmM's' respectively) even in presence of 1% DMSO (Table 8). Interestingly, the kinetic parameters for the conversion of the investigated amyloid peptides did not change dramatically with increasing size, suggesting only moderate effects of the C-terminal part of AP on QC catalysis. Therefore, due to better solubility and experimental handling, the further investigations concerning N-terminal aminopeptidase processing of these peptides were performed using the smaller fragments of As, [Gln 3 ]AP1-11a, [Glna]Ap3-11a and Ap3-11a. Table 8: Kinetic parameters for conversion of N-terminally Gin-containing peptides by recombinant human 0C in buffer solution containing 1% DMSO Peptide KM (pM) kat (s') keaIKm (mM' 1 s') [GIn 3 Ap3-1 1 a 87 ±3* 55 ±11 632 ±10* [Gln 3 ]AI3-11a 155 ±4 41.4 ±0.4 267 ±4 (Gin 3 JA3-21a 162 ±12 62 ±3 383 ±10 [Gln3]Ap3-40 89 ±10 40 ±2 449 ±28 Glucagon(3-29) 19 ±1 10.0 ±0.2 526 ±17 75 Determined in absence of DMSO Example 10: Turnover of Ap3-11a and A03-21a by recombinant human OC The incubation of A 3-1 1a and A@3-21a in presence of 0C revealed that in contrast to previous work, glutamate-containing peptides can also serve as OC-substrates (Figures 15C and D). The QC-catalyzed formation of [pGlu 3 ]A03-1 1a and [pGlu 3 ]A03 21a was investigated at pH 5.2 and 6.5, respectively. If the QC-inhibitor benzimidazole was added to the solution before starting the assay by addition of QC, substrate conversion resulting in [pGlu 3 ]A03-1 1a or [pGlu 3 ]AO3-21a was suppressed (Figures 15E and F). If QC was boiled before addition, formation of the pGlu-peptides was negligible (Figures 15A and B). Example 11: pH-dependency of the papaya OC-catalyzed cyclization of Gin ONA and Glu-ONA Papaya QC converted Glu-#NA in a concentration range up to 2 mM (which was limited by substrate solubility) in accordance with Michaelis-Menten kinetics (Figure 16). Inspection of turnover versus substrate concentration diagrams for the QC catalyzed conversion of Glu-pNA, studied between pH 6.1 and 8.5, revealed that for this Glu-substrate both parameters, Km and kat changed in a pH-dependent manner (Figure 16). This is in contrast to the previously described QC-catalyzed glutamine cyclization, for which only changes in Km were observed over the given pH range (Gololobov, M. Y., Song, I., Wang, W., and Bateman, R. C. (1994) Arch Biochem Biophys 309, 300-307). Subsequently, to study the impact of the proton concentration during Glu- and Gin cyclization, the pH-dependence of cyclization of Glu-#NA and Gln-#iNA under first order rate-law conditions (i.e. substrate concentrations far below K-values) was investigated (Figure 17). The cyclization of glutamine has a pH-optimum at pH 8.0, in contrast to the cyclization of glutamic acid which showed a pH-optimum of pH 6.0.
76 While the specificity constants at the respective pH-optima differ approximately 80,000-fold, the ratio of QC versus EC activity around pH 6.0, is only about 8,000. The nonenzymatic pGlu-formation from Gln-fiNA investigated at pH 6.0, was followed for 4 weeks and revealed a first-order rate constant of 1.2*107 s'. However, during the same time period, no pGlu-pNA was formed from Glu-#NA, allowing to estimate a limiting rate constant for turnover of 1.0*104 s-1. Example 12: Enzyme inactivation/Reactivation Procedures An aliquot of human 0C (0.1-0.5 mg, 1 mg/ml) was inactivated overnight by dialysis against a 3000-fold excess of 5 mM 1,10-phenanthroline or 5 mM dipicolinic acid in 0.05 M Bis-Tris/HCl, pH 6.8. Subsequently, the inactivating agent was carefully removed by dialysis (3 cycles, 2000-fold excess) of the samples against 0.05 M Bis Tris/HCl, pH 6.8, containing 1 mM EDTA. Reactivation experiments were performed at room temperature for 15 minutes using Zn*, Mn", Ni", Ca", K* and Co* ions at concentrations of 1.0, 0.5, 0.25 mM in 0.025 M Bis-Tris, pH 6.8 containing 0.5 mM EDTA. OC activity assays were performed in 0.05 M Tris/HCI, pH 8.0, containing 2 mM EDTA, in order to avoid a rapid reactivation by traces of metal ions present in buffer solutions. The inhibition of porcine QC by 1,10-phenanthroline has already been described (Busby, W. H. J. ot al. 1987 J Biol Chem 262, 8532-8536, Bateman, R.C.J. et al. 2001 Biochemistry 40). However, the fact that EDTA has been shown to have an activating effect on QOC catalysis suggested that inhibition by phenanthroline is not due to metal chelation (Busby, W. H. J. et al. 1987 J Biol Chem 262, 8532-8536, Bateman, R.C.J. et al. 2001 Biochemistry 40). Also, in addition to being inhibited by 1,10-phenanthroline, human 0C catalyzed substrate cyclization was abolished in presence of dipicolinic acid and 8-hydroxyquinoline, other inhibitors of metalloenzymes. These chelators inhibited 0C in a competitive and time-dependent manner, i.e., already competitively inhibited initial activity was found to be further reduced after prolonged incubation with the compounds (Figure 18,19). Interestingly, EDTA did not show remarkable inhibition regardless of incubation time or under any conditions.
77 Human QC was almost completely inactivated after extensive dialysis against 5 mM 1,10 phenanthroline or 5 mM dipicolinic acid. After repeated dialysis overnight against chelator-free buffer solutions, QC activity was partially reactivated up to 50- 60%. However, when dialyzed against buffers containing 1 mM EDTA, no reactivation was observed. Near-total restoration of QC activity after inactivation by either dipicolinic acid or 1,10 phenanthroline was achieved by incubating the protein for 10 minutes with 0.5 mM ZnSO 4 in presence of 0.5 mM EDTA (Figure 20). Partial restoration of QC activity was similarly obtained using Co+ and Mn* ions for reactivation. Even in the presence of 0.25 mM Zn" a reactivation up to 25% of the original activity was possible. No reactivation was observed applying Ni", Ca" or K' ions. Similarly, incubation of fully active QC with these ions had no effect on the enzyme activity. Example 13: effect of a combination of a QC inhibitor and a DPIV inhibitor 1. Assay In accordance with example 8 of the present invention (p. 72), the measurements were carried out with two short N-terminal peptide sequences of A[3-40/42, (Gln 3 ]-AP1-11 (sequence: DAQFRHDSGYE) and [Gln 3 ]A33-1 1, which contain a glutamine instead of an glutamic acid residue in the third position. Cleavage by DPIV and cyclization of the N terminal glutamine residue by QC of the two peptides was tested using MALDI-TOF mass spectrometry as described in example 3 (pp. 57-58). Measurements were carried out using recombinant human DPIV and QC. 2. Results As shown in Figures 5 to 15 of the present invention, the inhibition of DPIV and QC is a strategy to reduce either the generation of the QC-substrate (A33--1 a) or the cyclization of the N-terminus to produce [pGlu]AD(3-1 1), respectively. In Figure 22, the combined approach is exemplified shown with two highly potent inhibitors of QC (1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea) and DPIV (Valyl-Pyrrolidine, Val-Pyrr). Again, incubation of [Gln 3 ]AP(1-11)a (m/z 1323) with DPIV and QC results in intermediate production of [GIn 3 ]AP(3-1 )a (ml/z 1137) and 77a in formation of [pGlu]A3(3-11)a (m/z 1120) by consecutive catalysis of both enzymes (A). Inhibition of DPIV alone reduces the velocity of formation of [Gln 3 ]A J(3-1 l)a (the substrate of QC), and therefore, also [pGlu]A3(3-1 1)a is slightly reduced, comparing Figure 1 (A) and (B). The same was observed, if the QC-mediated cyclization of [Gln 3 ]A(3-l l)a was inhibited by applying the QC inhibitor 1-(3-(IH-imidazol-1 yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea (C): the formation of [pGlu]AP(3-1 ])a was diminished. The appearance of [pGlu]A3(3-1 1)a was, however, almost abolished, if both inhibitors were present, Under these conditions both the generation of the substrate of QC ([Gln 3 ]A3(3-1 )a, m/z 1137) and the QC catalysis were inhibited, resulting in a highest efficacy to suppress the generation of [pGlu]A3(3-ll)a (marked by an asterisk). Thus, combination of both DPIV and QC inhibiting strategies clearly displays highest efficacy to diminish the pGlu-formation.
Claims (47)
1. Use of effectors of glutaminyl cyclase (QC) for the preparation of a medicament for c) the treatment of diseases in mammals that can be treated by modulation of QC activity in vivo and/or d) the modulation of physiological processes based on the action of pGlu containing peptides caused by modulation of QC activity.
2. The use according to claim 1 for alteration of the conversion of N-terminal glutamic acid or glutamine residues to pyroglutamic acid residues in at least one QC-substrate selected from Ap3-40/42, [Gin 3 ]Ap3-40/42, [Glu")AP1 1-40/42, [GIn"]A 11-40/42, [Gln')Gastrins (17 and 34), [Gln']Neurotensin, [Gln']FPP, [Gln']TRH, (Gln']GnRH, (Gln']CCL 2, [GIn']CCL 7, [Gln']CCL 8, [Gln']CCL 16, [GIn']CCL 18, [GIn']ELA, [Gln']Fractalkine, [Gln']Orexin A, [Gln 3 ]glucagon3-29 and [Gln 5 ]substance P5-11.
3. The use according to claim 1 for the treatment of Alzheimer's disease and Down Syndrome.
4. The use according to claim 1 for regulation and/or control of male fertility.
5. The use according to claim 1 for the treatment of a disease selected from ulcer disease and gastric cancer with or w/o Heliobacter pylori infections, pathogenic psychotic conditions, schizophrenia, infertility, neoplasia, inflammatory host responses, cancer, malign metastasis, melanoma, psoriasis, rheumatoid arthritis, atherosclerosis, impaired humoral and cell-mediated immune responses, leukocyte adhesion and migration processes in the endothelium, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance and impaired regulation of body fluids.
6. The use according to claim 1 for the stimulation of gastrointestinal tract cell proliferation, preferably proliferation of gastric mucosal cells, epithelial cells, acute acid secretion and for the differentiation of acid producing parietal cells and histamine-secreting enterochromaff in-like cells. 79
7. The use according to claim 1 for the suppression of myeloid progenitor cell proliferation.
8. The use according to claim 1 for the treatment of a disease selected from Huntington disease and Kennedy's disease.
9. The use according to any one of the preceding claims, wherein the effector of QC is administered in combination with an inhibitor of DP IV or DP IV-like enzymes and/or an aminopeptidase-inhibitor.
10. The use according to claim 9, wherein the H-isoAsp-Ala-OH generating activity of a DP IV-like enz-yme is blocked.
11.The use according to claims 9 or 10, wherein the DP IV-like enzyme is OP 11.
12. A pharmaceutical composition for parenteral, enteral or oral administration, characterized in that it contains at least one effector of QC optionally in combination with customary carriers and/or excipients.
13.A pharmaceutical composition for parenteral, enteral or oral administration, characterized in that it contains at least one effector of OC in combination with at least one inhibitor of DP IV or DP IV-like enzymes and/or at least one aminopeptidase-inhibitor, optionally in combination with customary carriers and/or excipients.
14. Use of pharmaceutical compositions according to claims 12 or 13 for the in vivo modulation of the enzyme activity of QC and/or DP IV and DP IV-like enzymes and/or aminopeptidases.
15.The use according to claim 14, wherein the H-isoAsp-Ala-OH generating activity of a DP IV-like enzyme is blocked.
16.The use according to claims 14 or 15, wherein the DP IV-like enzyme is DP 1l.
17. The use according to any one of claims 14 to 16 for alteration of the conversion of N-terminal glulamic acid or glutamine residues to pyroglutamyl (5-oxo-prolyl) residues in at least one QC-substrate selected from A03,40/42, [Gln]A03-40/42, [Glu"]Ap1 1-40/42, [GIn " ] AP1 1-40/42, [Gtn']Gastrins (17 and 34), [Gln']Neurotensin, [GIn']FPP, (GIn'jTRH, (Gln 1 ]GnRH, [GIn']CCL 2, [GIn']CCL 7, (Gln']CCL 8, [Gln']CCL 16, [Gln']CCL 18, [Gln']ELA, [Gln']Fractalkine, [Gln']Orexin A. 80
18.The use according to any one of the claims 14 to 16 for the treatment of Alzheimer's disease and Down Syndrome.
19. The use according to any one of the claims 14 to 16 to modulate male fertility by administration of QC effectors.
20. The use according to any one of the claims 14 to 16 for the treatment of a disease selected from the group consisting of ulcer disease and gastric cancer with or w/o Heliobacter pylori infections, pathogenic psychotic conditions, schizophrenia, infertility, neoplasia, inflammatory host responses, cancer, malign metastasis, melanoma, psoriasis, rheumatoid arthritis, atherosclerosis, impaired humoral and cell-mediated immune responses, leukocyte adhesion and migration processes in the endothelium, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance and impaired regulation of body fluids.
21.The use according to any one of the claims 14 to 16 for the stimulation of gastrointestinal tract cell proliferation, preferably proliferation of gastric mucosal cells, epithelial cells, acute acid secretion and for the differentiation of acid producing parietal cells and histamine-secreting enterochromaff in-like cells.
22. The use according to any one of the claims 14 to 16 for the suppression of myeloid progenitor cell proliferation.
23. A screening method for the identification and selection of effectors of QC comprising the following steps: a) Contacting said compounds QC under conditions which would permit binding therebetween; b) Adding a substrate of QC; c) Monitoring the conversion of the substrate or optionally measuring the residual QC activity; and d) Calculating changes in the substrate conversion and/or enzyme activity of QC to identify an activity modifying effector of QC.
24. A screening method for the identification and selection of effectors which interact directly or indirectly with the active-site bound metal ion of QC comprising the following steps: 81 a) Contacting said compounds 0C under conditions which would permit binding there between; b) Adding a substrate of QC; c) Monitoring the conversion of the substrate or optionally measuring the residual QC activity; and d) Calculating changes in the substrate conversion and/or enzyme activity of QC to identify an activity modifying effector of QC.
25.The effectors of OC, which are identified by the screening methods of claims 23 or 24.
26.A method of treating diseases in mammals that can be treated a) by modulation of 0C activity in vivo and/or b) by the modulation of physiological processes based on the action of pGlu containing peptides caused by modulation of QC activity comprising administering to said mammals a therapeutically effective amount of at least one effector of glutaminyl cyclase (QC) for modulating QC activity on Gin or GIu peptides.
27. The method according to claim 26 wherein said modulating 0C activity results in the alteration of the conversion of N-terminal glutamic acid or glutamine residues to pyroglutamic acid residues in at least one QC-substrate selected from the group consisting of Ap3-40/42, (Gin 3 ]AP3-40/42, [Glu"JA11-40/42, [Gln']Ap11 40/42, [GIn']Gastrins (17 and 34), [Gln']Neurotensin, [Gin']FPP, [Gln']TRH, [Gln']GnRH, [Gin']CCL 2, [Gln']CCL 7, [Gln']CCL 8, [Gln']CCL 16, [Gln')CCL 18, (Gln']ELA, [G In']Fractalkine, [Gln']Orexin A, [Gln 3 ]glucagon3-29 and [Gin 5 ]substance P5-11.
28.The method according to claim 26 for the treatment of Alzheimer's disease and Down Syndrome.
29. The method according to claim 26 wherein said modulation of QC activity comprises regulation and/or control of male fertility.
30.The method according to claim 26 wherein said disease is selected from the group consisting of ulcer disease and gastric cancer with or w/o Heiobacter pylor infections, pathogenic psychotic conditions, schizophrenia, infertility, neoplasia, inflammatory host responses, cancer, malign metastasis, melanoma, psoriasis, 82 rheumatoid arthritis, atherosclerosis, impaired humoral and cell-mediated immune responses, leukocyte adhesion and migration processes in the endothelium, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance and impaired regulation of body fluids.
31. The method according to claim 26 wherein said treatment results in stimulation of gastrointestinal tract cell proliferation, proliferation of gastric mucosal cells, epithelial cells, acute acid secretion and for the differentiation of acid producing parietal cells and histamine-secreting enterochromaff in-like cells.
32. The method according to claim 26 wherein said treatment results in suppression of myeloid progenitor cell proliferation.
33.The method according to any one of the claims 26-32, wherein the effector of QC is administered in combination with an inhibitor of DP IV or DP IV-like enzymes and/or an aminopeptidase-inhibitor.
34.The method according to claim 33, wherein the H-isoAsp-Ala-OH generating activity of a DP IV-like enzyme is blocked.
35. The method of treatment according to claim 34, wherein the DP IV-like enzyme is DP II.
36.A pharmaceutical composition for parenteral, enteral or oral administration, comprising at least one effector of QC optionally in combination with a therapeutically acceptable carrier and/or excipient.
37.The pharmaceutical composition of claim 36 further comprising at least one inhibitor of DP IV or DP IV-like enzymes and/or at least one aminopeptidase inhibitor.
38. A method of treating diseases in mammals that can be treated a) by modulation of OC activity in vivo and/or b) by the modulation of physiological processes based on the action of pGlu containing peptides caused by modulation of QC activity and/or the activity of DP V and DP IV-like enzymes and/or aminopeptidase activity in vivo comprising administering to said mammals a pharmaceutical compositions according to claims 36 or 37. 83
39,The method according to claim 38 for alterating the conversion of N-terminal glutamic acid or glutamine residues to pyroglutamyl (5-oxo-prolyl) residues in at least one QC-substrate wherein said substrate is selected from the group consisting of Ap3-40/42, [Gln 3 ]AP3-40/42, [Glu"]Ap11-40/42, [Gln"]AP11-40/42, [Gin']Gastrins (17 and 34), [Gin']Neurotensin, [Gln')FPP, [Gln']TRH, [Gln']GnRH, [Gln']CCL 2, {Gln']CCL 7, [GIn']CCL 8, [Gln']CCL 16, [Gln']CCL 18, [Gln']ELA, [GIn']Fractalkine, [Gln']Orexin A.
40.The method according to claim 38 for the treatment of Alzheimer's disease and Down Syndrome.
41.The method according to claim 38 to modulate male fertility.
42.The method according to claim 38 for the treatment of a disease selected from the group consisting of ulcer disease, gastric cancer with or w/o Heliobacter pylori infections, pathogenic psychotic conditions, schizophrenia, infertility, neoplasia, inflammatory host responses, cancer, malign metastasis, melanoma, psoriasis, rheumatoid arthritis, atherosclerosis, impaired humoral and cell-mediated immune responses, leukocyte adhesion and migration processes in the endothelium, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance and impaired regulation of body fluids.
43. The method according to claim 38 for stimulating gastrointestinal tract cell proliferation, stimulating proliferation of gastric mucosal cells, epithelial cells, acute acid secretion and for stimulating the differentiation of acid producing parietal cells and histamine-secreting enterochromaffin-like cells.
44.The method according to claim 38 for suppressing myeloid progenitor cell proliferation.
45.A screening method for the identification and selection of effectors of OC comprising the following steps: a) Contacting said compounds with OC under conditions which would permit binding there between; b) Adding a substrate of QC; c) Monitoring the conversion of the substrate or optionally measuring the residual 0C activity; and 84 d) Calculating changes in the substrate conversion and/or enzyme activity of OC to identify an activity modifying effector of QC.
46.A screening method for the identification and selection of effectors which interact directly or indirectly with the active-site bound metal ion of QC comprising the following steps: a) Contacting said compounds with QC under conditions which would permit binding therebetween; b) Adding a substrate of QC which is subject to conversion by 0C; c) Monitoring the conversion of the substrate or optionally measuring the residual 0C activity; and d) Calculating changes in the substrate conversion and/or enzyme activity of QC wherein changes may be used to identify an activity modifying effector of QC.
47. The effectors of OC, which are identified by the screening methods of claims 45 or 46.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011265545A AU2011265545B2 (en) | 2003-05-05 | 2011-12-23 | Use of effectors of glutaminyl and glutamate cyclases |
AU2013211539A AU2013211539B2 (en) | 2003-05-05 | 2013-08-02 | Use of effectors of glutaminyl and glutamate cyclases |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/468,043 | 2003-05-05 | ||
US60/468,014 | 2003-05-05 | ||
US60/512,038 | 2003-10-15 | ||
AU2009227925A AU2009227925B2 (en) | 2003-05-05 | 2009-10-23 | Use of effectors of glutaminyl and glutamate cyclases |
AU2011265545A AU2011265545B2 (en) | 2003-05-05 | 2011-12-23 | Use of effectors of glutaminyl and glutamate cyclases |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2009227925A Division AU2009227925B2 (en) | 2003-05-05 | 2009-10-23 | Use of effectors of glutaminyl and glutamate cyclases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2013211539A Division AU2013211539B2 (en) | 2003-05-05 | 2013-08-02 | Use of effectors of glutaminyl and glutamate cyclases |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2011265545A1 true AU2011265545A1 (en) | 2012-02-02 |
AU2011265545B2 AU2011265545B2 (en) | 2013-08-08 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009227925B2 (en) | Use of effectors of glutaminyl and glutamate cyclases | |
EP1961416B1 (en) | Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis. | |
AU2004283461B2 (en) | Use of effectors of glutaminyl and glutamate cyclases | |
AU2011265545A1 (en) | Use of effectors of glutaminyl and glutamate cyclases | |
AU2013211539A1 (en) | Use of effectors of glutaminyl and glutamate cyclases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |